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ADVISER Prof Liam Chong Kin
Message from the President of the Malaysian Thoracic Society
It gives me great pleasure to welcome all of you to this 8th Annual Congress of the
Malaysian Thoracic Society which is held to coincide with the General Annual Meeting
of the Society.
Dr Hamidah Shaban, the Chairperson of the Organizing Committee of this meeting,
together with her team, has prepared an interesting and exciting scientific programme
which covers a wide range of common respiratory disorders relevant to our clinical
practice especially in Malaysia. In line with the theme of the Congress, “Practical
Respiratory Medicine”, we have invited a distinguished faculty of local, regional and international speakers to discuss
issues such as asthma and COPD, respiratory infections, lung cancer, respiratory radiology, respiratory emergencies
and chronic cough. Diagnostic/interventional respiratory procedures and respiratory physiotherapy shall be covered in
depth in the Pre-Congress workshops.
I hope you will gain invaluable knowledge and skills at this Congress and together work towards our common goal
of elevating the standard of care for our patients with respiratory problems. I also hope that this Congress will provide
you the opportunity to meet up with old friends and to make new ones. Last but not least, I would like to express
my sincere thanks to all who has lent their support to make this Congress a success.
Prof Liam Chong Kin
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Message from the Organising Chairperson
On behalf of the Organising Committee, I warmly welcome you to the 8th Annual Congress
of the Malaysian Thoracic Society.
For this year’s Congress, we have chosen “Practical Respiratory Medicine” as the theme.
It is aimed to meet the needs of the General and Respiratory Physicians in managing
respiratory diseases in the country. There are two Pre-Congress Workshops,
eight Scientific Symposia, two Plenary Lectures, Grand Rounds and Free Paper
Presentations.
The Pre-Congress Workshops will be on ‘Diagnostic and Interventional Respiratory Procedures’ and “Respiratory
Physiotherapy”. The “Respiratory Physiotherapy” workshop which is included for the first time in MTS Congress,
will give the clinicians some knowledge on the role of physiotherapy in the management of respiratory diseases and
how to set up Pulmonary Rehabilitation Programme, which is available in very few hospitals in Malaysia.
The Congress will also cover common respiratory diseases such as Respiratory Infections, Allergy, Asthma, Lung Cancer
and Respiratory Emergencies. The “Respiratory Radiology” symposium was added because radioimaging is an integral
part of the practice of respiratory medicine.
With the support from various parties, we are able to put together a faculty of eminent speakers, both from local and
abroad, who are the experts in their own field.
Lastly, we hope you will find the Congress informative and stimulating.
Thank you.
Dr Hamidah Shaban
3
M A L A Y S I A N  T H O R A C I C  S O C I E T Y  –  8 t h A N N U A L  C O N G R E S S
Programme Summary
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Daily Programme
F R I D AY, 1 5  J U LY  2 0 0 5
0700 – 1730 REGISTRATION
0825 – 0830 Welcome Address 
PRE-CONGRESS WORKSHOP 1 BALLROOM B
Diagnostic and Interventional Respiratory Procedures
CHAIRPERSONS: PROF LIAM CHONG KIN / DATO’ DR ABDUL RAZAK MUTTALIF
0830 – 0900 BAL: How to Maximize Yield  [page 13]
Assoc Prof Roslan Harun
0900 – 0930 Bronchoscopic Biopsy Techniques (EBB, TBLB,TBNA): Which Technique for
which Patient [page 13]
Assoc Prof Roslan Harun
0930 – 1000 Interventional Bronchoscopy 2005: Who, What, When and How  [page 14]
Prof Philip Eng
1000 – 1030 TEA
1030 – 1100 Argon Plasma Coagulation, Laser, Electrocautery: When and How
Dr Alan Ng
1100 – 1130 Airway Stenting  [page 14]
Prof Philip Eng
1130 – 1200 Bronchoscopic Foreign Body Removal in Adults  [page 14]
Prof Philip Eng
1200 – 1230 Medical Thoracoscopy
Dr Alan Ng
1230 – 1430 Lunch Symposium (Bristol-Myers Squibb) BALLROOM C
CHAIRPERSON: PROF LIAM CHONG KIN
CAP Guidelines and Recommendations – Applicability in the Asian Population
Dr Aileen Wang
FRIDAY PRAYERS
 
PRE-CONGRESS WORKSHOP 2 BALLROOM B
Respiratory Physiotherapy
CHAIRPERSONS: ASSOC PROF ROSLINA MANAP / DR NORRASHIDAH WAHAB
1430 – 1500 Physiotherapy in Respiratory Diseases [page 15]
Ms Ayiesah Hj Ramli
1500 – 1530 Excess Bronchial Secretions – How can a Physiotherapist Help?  [page 15]
Assoc Prof Sue Jenkins
1530 – 1600 Physiotherapy for Children with Respiratory Diseases: When and What?  [page 16 – 18]
Ms Katijjahbe Mohd Ali
1600 – 1630 Practical Aspects of Setting up a Pulmonary Rehabilitation Program  [page 19]
Assoc Prof Sue Jenkins
1630 – 1700 Pulmonary Rehabilitation: The HUKM Experience  [page 19 – 20]
Ms Katijjahbe Mohd Ali
1700 – 1730 TEA
1730 – 1830 Community Acquired Pneumonia: Review of Malaysian Guidelines
Datin Dr Aziah Ahmad Mahayiddin
1930 – 2200 Evening Symposium (AstraZeneca) BALLROOM C
CHAIRPERSONS: PROF LIAM CHONG KIN / DR ZAINUDIN MD ZIN
1930 Introduction by Chairperson
Prof Liam Chong Kin
1945 Burden of Asthma in Malaysia
Dr Zainudin Md Zin
2000 Asthma Management – The New Frontier
Prof Roland Buhl
2045 Q & A
2100 DINNER
S A T U R D AY, 1 6  J U LY  2 0 0 5
0815 – 0900 Plenary Lecture 1 BALLROOM B
CHAIRPERSON: DR HAMIDAH SHABAN
Asthma and COPD – Update 2005  [page 20]
Prof Roland Buhl 
0900 – 1030 Symposium 1A : Respiratory Infections BALLROOM B
CHAIRPERSONS: ASSOC PROF RICHARD LOH / DR NORHAYA RAZALI
Pneumonia in Immunocompromised Patients  [page 21]
Dr Mahiran Mustafa 
Hospital Acquired Pneumonia: Prevention and Management  [page 21]
Prof Liam Chong Kin   
Bronchiectasis vs Diffuse Panbronchiolitis – Is the Treatment Different?  [page 22]
Dr Zainudin Md Zin
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Symposium 1B : Interstitial Lung Disease (ILD) In Children SENTRAL LINK
CHAIRPERSONS: ASSOC PROF JESSIE DE BRUYNE / DR PATRICK CHAN
Diffuse Parenchymal Lung Disease in Children  [page 22]
Dr Rus Anida Awang
Interstitial Lung Disease in Children – The European Experience  [page 23]
Dr Petr Pohunek
Interstitial Lung Disease in Children – Recommendations for the Management  [page 23]
Dr Petr Pohunek
1030 – 1100 TEA
1100 – 1230 Symposium 2A: Lung Cancer BALLROOM B
CHAIRPERSONS: DR GEORGE KUTTY SIMON / DR PANG YONG KEK
Staging of Lung Cancer: An Update  [page 24]
Prof Liam Chong Kin
Non-surgical management of locally advanced and metastatic non-small cell
lung cancer: An update  [page 25]
Assoc Prof Fuad Ismail
Surgical Management of Lung Cancer and An Update  [page 25]
Dr Mohd Ezani Mohd Taib
Symposium 2B: Airway Disorders In Children SENTRAL LINK
CHAIRPERSONS: DR NORZILA ZAINUDIN / DR MAZIDAH RASID
Tracheomalacia and Bronchomalacia  [page 26]
Dr Petr Pohunek
Bronchiolitis Obliterans  [page 26]
Dr Patrick Chan
Flexible Bronchoscopy – My Personal Practice  [page 27]
Dr Petr Pohunek
1230 –  1400 Lunch Symposium (Merck Sharp & Dohme) BALLROOM C
CHAIRPERSON: DR GEORGE KUTTY SIMON
Asthma & Allergic Rhinitis – Past, Present & Future
Prof Ruby Pawankar
1400 –  1530 Symposium 3A: Respiratory Radiology BALLROOM B
CHAIRPERSONS: DATIN DR AZIAH AHMAD MAHAYIDDIN / DR JAMALUL AZIZI
Unusual Chest Xrays  [page 27]
Prof Philip Eng
HRCT of Interstitial Lung Diseases  [page 28]
Assoc Prof Gnana Kumar  
Role of PET Scan in Respiratory Diseases  [page 28]
Dr Low Su Ying    
Symposium 3B: Year in Review SENTRAL LINK
CHAIRPERSONS: DR NORRASHIDAH WAHAB / DR RUS ANIDA AWANG
Childhood Asthma  [page 29]
Assoc Prof Jessie De Bruyne
Respiratory Infections  [page 30]
Dr Petr Pohunek
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1530 – 1630 Free Papers [page 33 – 37] BALLROOM B
CHAIRPERSON: ASSOC PROF ROSLINA MANAP
1630 – 1730 Adult Grand Round BALLROOM B
CHAIRPERSONS: DR ZAINUDIN MD ZIN / DR I KUPPUSAMY
Paediatric Grand Round SENTRAL LINK
CHAIRPERSON: DR PATRICK CHAN
1730 – 1830 TEA / 15th MTS Annual General Meeting BALLROOM C
1930 – 2200 Evening Symposium (Boehringer-Ingelheim & Pfizer) BALLROOM B
CHAIRPERSON: PROF LIAM CHONG KIN
Air Trapping – A Paradigm Shift in the Management of COPD
Prof Donald A Mahler
2030 – 2200 Congress Dinner BALLROOM C
S U N D AY, 1 7  J U LY  2 0 0 5
0830 – 0915 Plenary Lecture 2 BALLROOM B
CHAIRPERSON: DR LIM KIM HATT
The Many Faces of GERD – “Acid Asthma” [page 30]
Prof Dato’ Goh Khean Lee
0915 – 1045 Symposium 4: Respiratory Emergencies BALLROOM B
CHAIRPERSONS: DR YAP BOON HUNG / DR CATHERINE WONG
Respiratory Failure: Update on Management
Assoc Prof Kamarudin Jaalam
Management of Massive Hemoptysis  [page 31]
Prof Philip Eng      
Recurrent Pneumothorax: Tips on Management
Dr Alan Ng   
1045 – 1115 TEA
1115 – 1245 Symposium 5: Miscellaneous BALLROOM B
CHAIRPERSONS: DR JEFFREY ABU HASSAN / DR FAUZI MD ANSHAR
Chronic Cough: How to Investigate and Treat  [page 31]
Assoc Prof Roslina Manap  
Primary Pulmonary Hypertension: Treatment Update  [page 31 – 32]
Dato’ Dr David Chew
Sarcoidosis: Issues in Diagnosis and Treatment  [page 32]
Assoc Prof Richard Loh
1245 – 1430 Lunch Symposium (GlaxoSmithKline) BALLROOM C
1245 Welcome Address by Dr Zainudin Md Zin, Chairman of the Asthma Council Meeting (ACM)
1255 Opening Address by Prof Liam Chong Kin, President of the Malaysian Thoracic Society
1305 Official Launch of ACM
1325 LUNCH
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a b s t r a c t s
PRE -CONGRESS  WORKSHOP  1
DIAGNOST IC  A ND  INTERV ENT IONA L  RES P IRATORY P ROC EDURES
BAL: HOW TO MAXIMIZE YIELD
ROSLAN HARUN
Respiratory Unit, Department of Medicine, Faculty of Medicine UKM, Kuala Lumpur, Malaysia
Bronchoalveolar lavage (BAL) is performed as part of routine bronchoscopy to sample the contents of the lower respiratory
tracts. BAL can provide information on the cellular and molecular components of the alveolar epithelial fluids. This technique
is particularly useful in the diagnosis of opportunistic infections. In certain noninfectious lung diseases, the BAL findings are
diagnostic and in others, it may contribute to the diagnosis and management of the diseases. BAL is performed after the
general inspection of the bronchial tree and before biopsy or brushing. The optimal fluid recovery occurs when the
bronchoscope completely occludes the bronchial lumen without “overwedging”, which may result in less fluid recovery.
Uncontrolled wall suction may cause airway collapse which will reduce the recovery of instilled fluid. In addition,
the excessive suction may cause trauma to the bronchial wall, and produce contamination of the lavage fluid with blood.
The BAL fluid recovery increases with increasing volume instilled in the lungs. The routine processing of the BAL specimens
will also be discussed.
PRE -CONGRESS  WORKSHOP  1
DIAGNOST IC  A ND  INTERV ENT IONA L  RES P IRATORY P ROC EDURES
BRONCHOSCOPIC BIOPSY TECHNIQUES (EBB, TBLB, TBNA):
WHICH TECHNIQUE FOR WHICH PATIENT
ROSLAN HARUN
Respiratory Unit, Department of Medicine, Faculty of Medicine UKM, Kuala Lumpur, Malaysia
The choice of biopsy techniques used in diagnostic bronchoscopy depends on the appearance, site and type of the lesions
or lung diseases. In patients with suspected lung cancer, the diagnostic yield of bronchoscopic biopsy is related to the site
and appearance of the tumour during the bronchoscopy. For a proximal and visible endobronchial tumour, up to 82% positive
rate for malignancy can be achieved with endobronchial biopsies (EBB). A combination of bronchial biopsies, brushings
and washings has been shown to increase the diagnostic yield in not only visible tumours, but also in tumours with normal
or non-specific appearances. Transbronchial needle aspiration (TBNA) has recently been used more widely. For visible
tumours, there is no different in the yield from TBNA and forceps biopsy. However, TBNA has been shown to be more
sensitive in detecting submucosal malignancies compared to forceps biopsy. In the staging of the lung cancer, TBNA is also
increasingly being used to sample the enlarged hilar or mediastinal lymph nodes. For peripheral pulmonary lesions,
the diagnostic yield of transbronchial lung biopsy varies according to the underlying disease, distribution of the disease and
the number of biopsy specimens taken. Diagnostic yields are usually high in patients with sarcoidosis and lymphangitis
carcinomatosis but low in interstitial pulmonary fibrosis. Fluoroscopy is helpful for localized lesions however it is not
necessary for diffuse lung diseases.
M A L A Y S I A N  T H O R A C I C  S O C I E T Y  –  8 t h A N N U A L  C O N G R E S S
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PRE -CONGRESS  WORKSHOP  1
DIAGNOST IC  A ND  INTERV ENT IONA L  RES P IRATORY P ROC EDURES
INTERVENTIONAL BRONCHOSCOPY 2005: WHO, WHAT, WHEN, AND HOW 
PHILIP ENG
Department of Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore
There is no doubt that Jean Francois Dumon is the father of Interventional Bronchoscopy. The development of the
Dumon-Harell rigid ventilating bronchoscope in 1990 was a major landmark. He should also be credited for training a whole
generation of interventional bronchoscopists. In this presentation, I will trace the humble origins of this field to the state of
the art today. I will also highlight some recent developments including recently published guidelines.
PRE -CONGRESS  WORKSHOP  1
DIAGNOST IC  A ND  INTERV ENT IONA L  RES P IRATORY P ROC EDURES
AIRWAY STENTING
PHILIP ENG
Department of Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore
Since the introduction of the Dumon stent and rigid ventilating bronchoscope by Dumon in 1990, rapid advances have been
made in this area. Today, airway stenting is the standard of care for patients with severe extrinsic benign and malignant major
airway disease that cannot be cured by surgical resection. Yet, the ideal stent has yet to come by and is the subject of intense
research all over the world. I will attempt to present the current state of the art in airway stenting and hope to clarify some
very common myths.
PRE -CONGRESS  WORKSHOP  1
DIAGNOST IC  A ND  INTERV ENT IONA L  RES P IRATORY P ROC EDURES
BRONCHOSCOPIC FOREIGN BODY REMOVAL IN ADULTS
PHILIP ENG
Department of Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore
Airway foreign bodies are uncommon in adults and the diagnosis is often missed for some time. In this presentation,
I will discuss both modalities of bronchoscopic removal ie flexible and rigid and their advantages and disadvantages in dealing
with this clinical problem.
PRE -CONGRESS  WORKSHOP  2
RES P IRATORY P H YS IOTH ERAPY
PHYSIOTHERAPY IN RESPIRATORY DISEASES
AYIESAH HJ RAMLI
Faculty of Allied Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
Chest physiotherapy is widely employed in the treatment of pulmonary disease to increase mucociliary transport.
There are many modalities used by physiotherapists to facilitate secretion clearance. The multimodalities approaches are
mobilization (Clarke, 1989), breathing exercises (Andersen et al, 1979), postural drainage (Woodhead and Tattersfield, 1987),
manual techniques (Vander Schance et al, 1986; Rivington- Law, 1981), autogenic drainage (David, 1991), mechanical aids
which includes positive expiratory pressure (PEP) (Falk et al, 1984), mechanical precursors and vibrators, oral high frequency
oscillators (George et al, 1985b) and flutters (Liardet, 1990). This airway clearance is also facilitated by mucociliary action,
counghing and the forced expiratory maneuver. Mucociliary clearance depends on normal active beating cilia coupled to a
mucous layer, the physical properties of which permit efficient cephalic movement. Coughing is essentially a reserve
mechanism which is most efficient in the central airways. It relies on a high linear airflow velocity which is generated by
ample flow, and airway narrowing may be curtailed because of inadequate flow in patients with COAD. Research evidence
have also demonstrated that clearance may be further assisted by drugs such as B2 agonists, theophylline, corticosteroids
and mucolytics agent with the incorporation of humidification, broncho-dilators and nebulisation which further enhances
facilitation of secretion clearance. All modalities have been proven to facilitate secretion clearance and the selection of each
modalities basically depends on patient compliance with each modalities used. Thus the usage of one or two other modalities
mention above can be used at the same time to facilitate secretion clearance. The goals of physiotherapists in management
of cardiorespiratory patients are to facilitate removal of secretions, to reexpand the airways, to prevent lung collapse,
to reduce the work of breathing, to facilitate increase exercise endurance and improve physical and physiological functioning.
PRE -CONGRESS  WORKSHOP  2
RES P IRATORY P H YS IOTH ERAPY
EXCESS BRONCHIAL SECRETIONS – HOW CAN A PHYSIOTHERAPIST HELP?
SUE JENKINS
Curtin University of Technology, Sir Charles Gairdner Hospital,
Asthma and Allergy Research Institute Inc, Australia
The problem of excess bronchial secretions is commonly encountered by physiotherapists and occurs in a number
of different lung conditions and in other clinical situations. This presentation is confined to the management of excess
bronchial secretions in adults who are not intubated.
The problem of excess bronchial secretions is managed using airway clearance techniques (ACTs) that aim to improve mucus
transport via the external application of forces and expiratory manoeuvres. This may involve the use of devices such as
the PEP mask or the Acapella. There is good evidence in people with hypersecretory lung disease that ACTs increase the
amount and/or rate of sputum expectorated and improve mucocililary clearance. In the long term, regular adherence with
ACTs has been shown to slow the decline in lung function.
There is a wide range of ACTs available and it is unknown which technique is the most effective. Further, forced expirations
are a part of the ACTs currently used and it is possible that these are the most important component.
The active cycle of breathing techniques (ACBT) is a commonly used ACT. It has the advantage of being simple to teach,
requires no equipment and is suitable for most patients. The ACBT has three components - breathing control (or quiet
breathing), thoracic expansion exercises (or deep breaths) and the forced expiration technique. The cycle is very flexible and
is adapted for the individual. The ACBT can be performed in sitting or in a gravity assisted drainage position. Percussion can
be added into the cycle and is most beneficial if the patient produces large amounts of sputum or very sticky sputum.
This presentation will provide the rationale and scientific evidence for ACT and will focus on the practical application of the
ACBT for the management of excess bronchial secretions.
M A L A Y S I A N  T H O R A C I C  S O C I E T Y  –  8 t h A N N U A L  C O N G R E S S
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PRE -CONGRESS  WORKSHOP  2
RES P IRATORY P H YS IOTH ERAPY
PHYSIOTHERAPY FOR CHILDREN WITH RESPIRATORY DISEASES: WHEN AND WHAT?
KATIJJAHBE MOHD ALI
Unit Fisioterapi, Jabatan Perkhidmatan Pemulihan Perubatan, Hospital Universiti Kebangsaan Malaysia,
Kuala Lumpur, Malaysia
The primary objective of chest physiotherapy in paediatric pulmonary diseases is to assist in the removal of tracheobronchial
secretions. Additional physiotherapy goals are to remove airway obstruction, reduce airway resistance, enhance gas
exchange and reduce the work of breathing. Breathing retraining and physical reconditioning are also incorporated whenever
applicable3.
Points to consider before administering physiotherapy interventions2, 4, 5
i. The possible deleterious effect of chest physiotherapy and suctioning in unstable patients
ii. Treatment must be carried out at least 1 hour following feeds to avoid aspiration
iii. The age of the child and his or her level of ability to cooperate (patient’s needs)
iv. The disease process
v. The participation of carers (family members, siblings etc.) in treatment
vi. The therapist’s skills/expertise and their personal evidence based choices regarding the effectiveness of these
techniques
Neonates and infants will be treated exclusively with traditional bronchial hygiene procedures2, 4, 6
Breathing games and activities can be incorporated in the regime when the child becomes a toddler2, 4, 6
As the children grow older, exercises for breathing retraining, physical reconditioning and postural exercises will be
included2, 6, 8
Measures for airway clearance that depend on breathing control such as autogenic drainage and positive expiratory
pressure masks become more applicable to older children as they will be able to coordinate the necessary breathing
maneuvers1, 2, 4, 6
Common physiotherapy interventions
A. Removal of secretions using bronchia hygiene technique 
– Extensively studied and reviewed
– Despite clinical observation that retained secretions give detrimental effect to respiratory function and anecdote
associations between secretion clearance and improvements in respiratory function, there is a dearth of high level of
evidence and wide accepted to support the secretion clearing technique1, 3, 8. Methods include the following:
i. Traditional methods (positioning for gravity assisted drainage of the airways, manual techniques for loosening
secretions and removals of secretions by directed coughing, and suctioning of the airway.
ii. Contemporary method involving huffing, forced expiratory techniques, positive expiratory pressure, flutter valve,
autogenic drainage high frequency chest compression 
Traditional approach 
Positioning / “ketchup bottle theory”
– Specific positioning for segmental drainage using tilt table/treatment tables. In infant and young children, therapist
lap and shoulder serve as treatment table 
– Baby held and comforted in 10 different drainage positions
– Modification of technique required reducing angle for head down position due to adverse pathophysiology
associated with various disease process
M A L A Y S I A N  T H O R A C I C  S O C I E T Y  –  8 t h A N N U A L  C O N G R E S S
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Manual techniques
a. Percussion
– Same as adult technique for percussion. The difference lies in the force used especially for premature baby.
The amount of force increased with age of baby
– Techniques differ due to the size of thorax 
b. Vibration
– Difficult to apply for infants with respiratory diseases who has a respiratory rate of 40 breath per minute or more
Coughing and suctioning
– Infant and children seldom cough on request. Toddlers and school aged children have language skills to
understand request but usually choose not to cough
– Imaginative means usually used include story telling, games to elicit cough
– Sometimes prompting children either to laugh or cry  (preferable the former) useful to produce productive cough.
– For children undergone surgery, splinting incision with hands or dolls pressed close child’s chest will promote
effective cough
– Airway suctioning is needed in neonate to remove secretions. Done carefully because significant risks even
when performed under the best circumstances
Contemporary approach
– Develop specifically for children and young adult with CF and for patient to participate actively in the treatment
– Widely used now for all individuals with chronic lung disease who produce copious sputum
Autogenic drainage / ACBT
– From practical experiences, it is a difficult technique and young children find difficult to learn. Need intense training
to use effectively
– Used commonly for patients who are highly motivated and old enough to control breathing (post op and obstructive
lung disease)
– Permit self treatment with active participation from patient
– Finding of effectiveness from few studies mix with some claim improvement in pulmonary function test and sputum
clearance8, 9
Positive Expiratory Pressure (PEP)
– Assist in secretion removal and reduce airway trapping by enhancing collateral ventilation
– PEP device offer various resistances and the child attempt to maintain level of pressure throughout exp phase
breaths followed by huff coughing to clear secretions10 – 15
– Recommended during bronchial drainage position
– Studies done show clear benefit in comparison with flutter and bronchial drainage8, 9
Flutter
– Clinical efficacy in children is shown in well-designed, controlled studies among hospitalized subjects10
B. Breathing exercises & retraining
– Requires voluntary participation from children. Where appropriate, use manual contact to teach breathing
– DeCesare suggest using physiologic tech e.g apply quick stretch to thorax to facilitate diaphragm and intercostal
muscle contraction to induce inspiration in baby or young children6
– Encourage participation in games that require deep breathing & control breathing
– Techniques commonly used are diaphragmatic breathing (protract abdomen during inhalation and active contract the
abdominal muscles during exhalation) and segmental breathing 
– Pursed lip breathing is also useful for reliving dyspnea and control breathing in children. Current technique use passive
expiration rather than forced expiration3
– Other useful adjunct such as incentive spirometer for post op pulmonary care 
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C. Physical training
– Children with respiratory diseases secondary to neuromuscular or musculoskeletal problems represent 2 distinct
groups important for physical training as they often experience dyspnea on exertion leading to abstention from any
activity3.
– Program should include exercises to improve strength and range of motion, body mechanic and postural stabilizaton
and endurance
– Exercises must be administer with close monitoring of sign of early fatigue, cynosis and dangerously high vital signs
due to reduction in oxygen con sumption3
Definitions of common physiotherapy techniques1
Directed cough – a technique that mimics the attributes of an effective spontaneous cough; the cough can be manually
assisted by application of external pressure to the epigastric region or thoracic cage during the expiratory phase (as in the
patient with neuromuscular disease); sometimes called quad coughing
Forced Expiratory technique (FET) – sometimes called huff coughing, this technique consists of one or 2 huffs from
mid-to-low lung volumes with the glottis open, followed by relaxed diaphragmatic breathing.
Chest physiotherapy (CPT) – this technique has included postural drainage, percussion and vibration. PD is a technique
in which the patient is positioned to facilitate gravity drainage of secretions from the airways. Percussion is a technique
of clapping the chest wall. Vibration applies fine shaking of the chest wall, usually during the expiratory phase. Percussion
and vibration can be applied using either manual or mechanical techniques
Positive Expiratory Pressure (PEP) – with this technique the patient exhales against a pressure of 10-20cm H2O.
Flutter – this technique use a device that produces PEP with oscillation in the airway during the expiratory phase
Active cycle of breathing technique (ACBT) – this technique includes breathing control, FET, Thoracic expansion tech and
may include CPT
Autogenic Drainage – This is a 3 level breathing sequence beginning at low lung volumes, followed by breathing at mid lung
volumes, follow by deep breathing and huff coughing.
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PRE -CONGRESS  WORKSHOP  2
RES P IRATORY P H YS IOTH ERAPY
PRACTICAL ASPECTS OF SETTING UP A PULMONARY REHABILITATION PROGRAM
SUE JENKINS
Curtin University of Technology, Sir Charles Gairdner Hospital,
Asthma and Allergy Research Institute Inc, Australia
A comprehensive pulmonary rehabilitation program comprises exercise training, patient education and outcome assessment.
The aims are to decrease breathlessness and fatigue, improve exercise tolerance and quality of life, increase participation
in physical and social activities, increase the patient’s knowledge about their condition and improve self management
and survival. In addition, an important aim of pulmonary rehabilitation is to decrease healthcare costs.
There is strong evidence from randomised controlled trials that pulmonary rehabilitation is beneficial for people with chronic
obstructive pulmonary disease however in clinical practice patients with other lung conditions are also offered pulmonary
rehabilitation and have been shown to benefit.
The strongest evidence exists for the exercise training component and in particular for lower limb endurance training.
Some patients with lung disease are breathless when using their arms for everyday activities and for this reason the inclusion
of unsupported upper limb exercise training is also important.
An out-patient program offered either in a hospital or in the community is the most common type of program. In this setting,
groups of patients attend supervised exercise classes and participate in education sessions. A minimum of two supervised
exercise classes a week is recommended and this should be supplemented by a home exercise program on two of three
additional days. Programs generally last for between six and twelve weeks however regular exercise beyond this is vital
to maintain the benefits of pulmonary rehabilitation.
To evaluate benefit from a program it is important to measure functional exercise capacity and health-related quality of life.
This is usually achieved with a field walking test and a validated questionnaire respectively which are completed prior to and
immediately following the program.
This presentation will briefly review the evidence for pulmonary rehabilitation and provide practical information for starting
up a program.
PRE -CONGRESS  WORKSHOP  2
RES P IRATORY P H YS IOTH ERAPY
PULMONARY REHABILITATION: THE HUKM EXPERIENCE
KATIJJAHBE MOHD ALI
Unit Fisioterapi, Jabatan Perkhidmatan Pemulihan Perubatan, Hospital Universiti Kebangsaan Malaysia,
Kuala Lumpur, Malaysia
Statistics for year 2001 – 2003 reported that out of the total new physiotherapy referrals, 70% was for cardiorespiratory
physiotherapy i.e. about 4200 cases per year. Following this increasing demand, one physiotherapist was sent to Singapore
to attend the Exercise Specialist Course and Certification by the American College of Sport Medicine (ACSM) in
December 2003. Subsequently, a clinical placement was done at Tan Tock Seng Hospital, Singapore in June 2005 for a duration
of 2 weeks. Operational policy for pulmonary rehabilitation was developed in January 2004.
A two-way discussion was held with between Assoc. Prof. Dr. Roslina Manap (Consultant Respiratory Physician, HUKM) and
the Head of Physiotherapy Unit in February 2004 to gather constructive input for the programme from both disciplines.
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Objectives for pulmonary rehabilitation are as follows:
1. To decrease respiratory symptoms such as dyspnoea and fatigue
2. Increase exercise tolerance & performance
3. Decrease psychological symptoms such as anxiety and depressions
4. Improve ability to perform ADL
5. Decrease hospitalisation and usage of medical resources
6. To enable patient to return to workplace
7. Improve patients’ knowledge on pulmonary diseases
8. Increase survival rate
The programme is divided into five phases;
Phase 1 – 2 weeks : pulmonary adaptation
Phase 2 – 3 weeks : increase adaptation
Phase 3 – 2 weeks : individual session
Phase 4 – 1 week : maintenance period
Phase 5 – 1 week : multidisciplinary education with manual booklet as part of daily diary to keep tab on their performance
• A graduation ceremony will be held once patients complete the 8 weeks programme successfully and a certificate will
be awarded.
• Programme has to be continued life long, at home or at day care centres
• Patients will be reviewed by physiotherapists once in every 3 months or half yearly
P L ENA RY L EC TURE  1
ASTHMA AND COPD – UPDATE 2005
ROLAND BUHL
Pulmonary Department, Mainz University Hospital, Germany
Asthma treatment should be tailored to the needs of the individual patient and easily adjusted in response to changes
in asthma symptoms and control. Recent large, long-term clinical trials have demonstrated that these standards can be
met even with fixed combinations of inhaled corticosteroids and long-acting _2-agonists in a single inhaler. The GOAL study
used an innovative endpoint of asthma control based on the GINA criteria to increase the dose until control was achieved.
The fixed combination containing formoterol, a rapid-acting _2-agonist with a long bronchodilator effect, even has the
potential for symptom-driven dosing. Future treatment options are β2-agonists with a duration of action of up to 24 h,
phosphodiesterase 4 inhibitors, and omalizumab (rhuMAb-E25), a recombinant humanized monoclonal anti-IgE antibody that
stops the allergic cascade by binding to free IgE.
A recent advance in COPD treatment is the demonstration that treatment with a fixed dose of an inhaled corticosteroid and
a long-acting β2-agonist improves lung function and quality of life, and reduces exacerbation more effectively than either drug
alone. Other improvements include tiotropium, a once-daily anticholinergic. In advanced clinical development are other
once-daily bronchodilators and combinations of anticholinergic drugs and β2-agonists. Increased understanding of the
pathogenesis of COPD has led to novel drugs aimed at inhibiting targets including phosphodiesterase-4, and various
inflammatory mediators. Furthermore, COPD is increasingly seen as a systemic disorder or, indeed may be a pulmonary
manifestation of a complex pathophysiological response to chronic inhalation of toxic irritants. Future therapy may involve
the development of new drugs that target systemic and metabolic manifestations that either result from or coexist
with chronic lung inflammation, hypoxia and cardiovascular disease in COPD.
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SYMPOSIUM 1A
PNEUMONIA IN IMMUNOCOMPROMISED PATIENT
MAHIRAN MUSTAFA
Physician and ID Consultant, Hospital Kota Bharu, Kota Bharu, Kelantan, Malaysia
In this era, all of us are seeing more immunocompromised patients especially those with HIV, cancer and patients who
received chemotherapy. Immunocompromised patients are at much higher risk of developing either community acquired
pneumonia or nasocomial pneumonia.
Pneumonia in this group of patients is more severe with higher mortality compared to the general. Besides common
organisms, they are at higher risk of developing opportunistic infection such as mycobacterium, viruses and fungi.
However, in many instances, the aetiology of the pneumonia is uncertain. Clinical judgement and rapid diagnostic are both
important in making the diagnosis. Prompt treatment is essential to improve the survival.
In many instances, the infection in immunocompromised can be prevented by treating underlying disease, use of prophylaxis
when indicated and ensuring cross infection does not happen. These measures are probably more effective than treating
the disease itself.
SYMPOSIUM 1A
HOSPITAL ACQUIRED PNEUMONIA: PREVENTION AND MANAGEMENT
LIAM CHONG KIN
Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Hospital acquired pneumonia (HAP), defined as pneumonia that occurs 48 hours or more after hospital admission, is the
second most frequent nosocomial infection, accounting for 15 to 20% of these infections. Usually occurring in patients with
underlying diseases, it increases nosocomial morbidity and mortality, prolongs hospital stay, and raises health care cost.
The incidence of HAP is highest in the ICU, especially among patients who are mechanically ventilated. Most epidemiological
and aetiological studies on nosocomial pneumonia have been focused on ventilator-associated pneumonia (VAP),
i.e., pneumonia that arises more than 48 – 72 hours after endotracheal intubation.
The bacteriology of HAP varies from one hospital to another, specific sites within the same hospital, and from one time period
to another. Local microbiological data and the specific clinical setting should be taken into account when selecting the initial
empirical antibiotic therapy. Each hospital and each ICU should ideally have their own antibiogram, which should be updated
as often as possible. While early-onset HAP and VAP, defined as occurring within the first 4 days of hospitalization, are more
likely to be caused by antibiotic-sensitive bacteria and usually carry a better prognosis, late-onset HAP and VAP (5 days or
more) are more likely to be caused by multidrug-resistant (MDR) pathogens, and are associated with increased patient
mortality and morbidity. Patients with early-onset HAP who have received antibiotics or who have been hospitalised within
the past 90 days or who are residents of healthcare-related facilities are at greater risk for colonisation with MDR pathogens
and infection by these organisms should be treated similar to patients with late-onset HAP or VAP.
Lower respiratory tract specimens should be collected for culture from all patients before the commencement (or change)
of antibiotic therapy, but collection of cultures should not delay the initiation of therapy in critically ill patients. Quantitative
or semi-quantitative cultures of lower respiratory tract specimens (endotracheal aspirate or bronchoalveolar lavage sample)
are recommended.
Prompt, appropriate antibiotic therapy in adequate doses improves the outcome of HAP with a lower attributable mortality.
Excessive antibiotic usage should be avoided by de-escalation or narrowing of initial therapy to the most focused regimen
possible, based on microbiological cultures and the clinical response of the patient. Shortening the duration of therapy to the
minimum effective period, as short as 7 to 8 days, is recommended for patients with uncomplicated HAP not caused
by Pseudomonas aeruginosa, who have received an initially appropriate antibiotic regimen and have had a good clinical
response.
M A L A Y S I A N  T H O R A C I C  S O C I E T Y  –  8 t h A N N U A L  C O N G R E S S
21
SYMPOSIUM 1A
BRONCHIECTASIS VS DIFFUSE PANBRONCHIOLITIS – IS THE TREATMENT DIFFERENT?
ZAINUDIN M ZIN
Damansara Specialist Hospital, Selangor, Malaysia
Bronchiectasis is a chronic respiratory disease of varied etiologies involving repeated infection and inflammation of large and
small airways causing permanent dilatation of the airways. The etiologies include an infectious insult, airway obstruction,
or a defect in host defence. Diffuse panbronchiolitis (DPB) is a distinct bronchiolar disease of unknown etiology that mainly
affects people in Japan, but sporadic cases have also been reported in China, Korea and in many other parts of the world.
Although the etiology is not understood, it appears to be inflammatory rather than an infectious disease.
Clinical presentation of an advanced DPB may not be distinguishable from that of bronchiectasis with chronic cough, copious
sputum production, exertional dyspnoea, wheezing and hypoxemia. Features of cor pulmonale and respiratory failure may
also be present. However, at the early stage of the illness the symptoms would be predominantly related to
bronchoconstriction where dyspnoea and wheezing are common. Clinical course of the disease is different from
bronchiectasis as it may often show rapid progression with fatal outcome especially if not appropriately treated. Pathological
and CT scan findings of DPB are highly characteristics and will be discussed. The recognition of these features is important
in order to make correct diagnosis and hence proper treatment. Prolonged treatment with low dose macrolides have been
reported to improve symptoms, lung functions, radiological changes and survival although most studies were non randomized
and not properly controlled. Other treatment modalities will be discussed.
SYMPOSIUM 1B
DIFFUSE PARENCHYMAL LUNG DISEASE IN CHILDREN
RUS ANIDA AWANG
Department of Paediatrics, Hospital Penang, Penang, Malaysia
Diffuse parenchymal lung disease in children represents a heterogeneous group of rare lung disorders that includes
interstitial lung disease, malignancy, lymphoproliferative disorder, chronic infection and vascular disorder. Interstitial lung
diseases in children are associated with considerable morbidity and mortality.
The clinical presentations are non-specific and variable. Respiratory signs and symptoms include tachypnoea, rapid shallow
breathing, retractions, crackles and cyanosis. Prolong illness will lead to failure to thrive and dyspnoea on exertion.
The diagnostic evaluation of a child with diffuse parenchymal lung disease is a step-by-step process, which includes
comprehensive history, physical examination, oxygen saturation (at rest, during exercise or during feeding), a plain chest
x-ray and a high resolution thin cut tomography scan of the chest. Pulmonary function studies in older children typically show
a restrictive pattern.
Invasive procedures are considered only when other techniques are inconclusive and tissue or alveolar fluid is deemed
necessary for a definitive diagnosis or for therapeutic decision. Open lung biopsy has long been considered the gold standard
for the diagnosis of diffuse parenchymal lung disease. Video-assisted thoracoscopic (VAT) lung biopsy is a less invasive
alternative approach in obtaining biopsies of parenchymal lung disease.
M A L A Y S I A N  T H O R A C I C  S O C I E T Y  –  8 t h A N N U A L  C O N G R E S S
22
SYMPOSIUM 1B
INTERSTITIAL LUNG DISEASE IN CHILDREN – THE EUROPEAN EXPERIENCE
PETR POHUNEK
Division of Paediatric Respiratory Diseases, Paediatric Department, 2nd Medical School of
Charles University, Prague, Czech Republic
Interstitial lung diseases (ILD) are rare heterogeneous conditions of both known and unknown origin. In children these
conditions have been studied mostly on small groups of patients and most of the approaches are derived from the adult
experience. The growing experience suggests more and more that the pediatric ILD is in many aspects different to the adult
conditions, mainly with regard to the pathogenesis, response to the treatment and prognosis.
The ERS Task Force on pediatric ILD organized a study that reviewed current practice in diagnosis and treatment of pediatric
ILD across Europe.
Data were collected across Europe on 185 children managed between 1997 and 2002. The mean duration of symptoms
before diagnosis was 6 months. Most children presented with cough and tachypnea, in two thirds of children younger than
2 years there was noted a significant failure to thrive. Specific diagnosis could be made in 52%. These included
hypersensitivity pneumonitis, pulmonary hemosiderosis, sarcoidosis, Langerhans cell histiocytosis and others. In 48%
the condition was labeled as “idiopathic”. In 78 children the diagnosis was based on non-invasive tests only (including BAL),
among those verified by lung biopsy, the open-lung biopsy was the mostly used method. In treatment, most of the children
were treated with steroids, second most frequently used drug was hydroxychloroquine. Other treatments included
azathioprine, cyclosporine, methotrexate, cyclophosphamide and some others. The outcome was better than reported
in adults. Improvement was registered in 74% of children, in 17% there was at least stabilization of the condition,
2% deteriorated and only 6% died.
Based on this cross-sectional study the Task Force recommended further multicentric prospective collaboration that would
include also gathering evidence for more precise genetic and pathological studies.
SYMPOSIUM 1B
INTERSTITIAL LUNG DISEASE IN CHILDREN – RECOMMENDATIONS FOR THE MANAGEMENT
PETR POHUNEK
Division of Paediatric Respiratory Diseases, Paediatric Department, 2nd Medical School of
Charles University, Prague, Czech Republic
DIAGNOSIS
Major attention must be paid to the early clinical presentation. Early symptoms are cough, exercise intolerance, inspiratory
crackles and tachypnea. Laboratory tests are mainly supportive but may help to exclude active infection, systemic
autoimmune disease or hypersensitivity reaction. Key imaging technique in this diagnostic process is the HRCT.
Bronchoscopy has been widely used for performing BAL. BAL may be diagnostic in cases when specific pathologic material
would be retrieved (hemosiderin-laden macrophages, CD1a positive cells etc.)
Pulmonary function tests are essential for the assessment of functional impairment and also for monitoring response to the
treatment. Main accent should be put on proper measurement of lung volumes including besides VC also TLC, FRC and RV.
Monitoring of oxygen saturation at rest and during exercise is very important as is also the assessment of diffusion capacity
(DLCO).
Histological evaluation of lung tissue is the final step in a series of diagnostic methods in non-conclusive situations.
It is recommended to perform targeted biopsy based on the HRCT. Open lung biopsy or video assisted thoracoscopy are the
most reliable methods.
TREATMENT
Most children profit from steroids, but also hydroxychloroquine has been show as effective, mostly in cases with expressed
fibrotic activity. Alternatively, azathioprine, cyclosporine, methotrexate and cyclophosphamide have been used.
Lung transplant remains the last resort in refractory progressive cases as it is the case in adults. In all cases the treatment
effect should be actively and carefully objectively monitored and any reduction or even stopping of the treatment should be
done in slow steps and in well documented full remission of the disease.
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SYMPOSIUM 2A
STAGING OF LUNG CANCER: AN UPDATE
LIAM CHONG KIN
Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
In many patients, a presumptive diagnosis of lung cancer can be made with a high degree of confidence based on the
patient’s age, risk factors, and the radiographic appearance of the tumour. It is often possible to predict whether the tumour
is more likely to be small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) (eg, rapid growth and marked
mediastinal lymphadenopathy without a peripheral lung lesion is typical of SCLC). Tissue confirmation of malignancy and
of the cell type must be obtained. The next issue is the extent of disease (staging), i.e., whether the hilar and mediastinal
lymph nodes are involved or not and whether intrathoracic or distant metastases are present or not. For staging, all patients
should undergo computed tomography (CT) of the thorax and upper abdomen to include the liver and adrenals. Patients with
signs and symptoms of systemic metastases (eg, fatigue, weight loss, poor appetite, neurological signs and symptoms, bone
pain) must be verified by imaging tests such as a brain CT or MRI and a bone scan. An exception to this approach is patients
with fairly obvious metastases in whom this can be confirmed by a biopsy of a metastatic site or by a skeletal plain radiograph
alone. MRI should be performed for tumours of the superior sulcus to define the relationship of the tumour to adjacent
neurovascular structures.
PET imaging, if available, is most useful for confirmation of the presumed extrathoracic stage in patients with intermediate
stages of lung cancer. PET imaging is particularly useful in patients with an atypical presentation, a solitary site of metastasis,
or with lesions that are indeterminate on other scans. For example, patients may present with an enlarged adrenal gland, an
indeterminate liver lesion, or a second pulmonary nodule. PET scan is an excellent study to either rule out or rule in malignant
involvement in these sites provided the lesion is > 1 cm in diameter. The role of PET imaging is limited in patients with strong
clinical signs of metastatic disease, or in patients with a clinical stage I lung cancer. With regard to intrathoracic staging, PET
imaging has a definite role in institutions where mediastinoscopy is not available, whereas the impact is limited when invasive
mediastinal staging is available. A positive PET result in the mediastinum should be confirmed by biopsy because the false
positive rate is 15 to 20%. It is unclear and controversial whether a mediastinal biopsy is needed in patients with clinical stage
II lung cancer who have no PET uptake in the mediastinum. In patients with a peripheral clinical stage I lung cancer,
it is reasonable not to order a PET scan for staging because the chances of finding either distant metastases or mediastinal
involvement on PET imaging are quite low.
Proof of the diagnosis of SCLC is generally obtained from whatever site and method is easiest. This may involve sputum
analysis, bronchoscopy, needle aspiration of a supraclavicular node or a pleural effusion, or transthoracic needle aspiration
of a mediastinal tumour.
NSCLC of stage IA/B and stage IIA/B are surgically resectable, provided that the patient has adequate pulmonary reserve and
is also medically fit for surgery. Resection offers the best chance for a cure of early-stage NSCLC. The 5-year survival rates for
pathologic stage IA disease (T1N0M0) and stage IB disease (T2N0M0) are 67% and 57%, respectively. Unfortunately,
few patients have their lung cancer detected while it is in an early stage. Although screening offers the hope that lung cancer
can be diagnosed at an earlier stage, with a greater chance of a cure, to date, no screening tool or test has been shown to
decrease lung cancer mortality. Spiral CT scan screening is the most promising tool currently available that offers
a substantial chance of detecting lung cancer at a smaller size. However, its impact on lung cancer mortality is yet to be seen.
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SYMPOSIUM 2A
NON-SURGICAL MANAGEMENT OF LOCALLY ADVANCED AND
METASTATIC NON-SMALL CELL LUNG CANCER: AN UPDATE
FUAD ISMAIL
Department of Radiotherapy & Oncology, Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
Lung cancer is the commonest cancer world-wide and is the commonest malignancy among Malaysian men.
Despite advances in imaging and tumour biology, late presentation is seen in three-quarters of patients, Cure is a remote
possibility for patients with stage III disease and is not possible in Stage IV disease. For the majority of patients, prolongation
of life with good symptom palliation and quality of life are key issues. For a highly selective group of fit patients with locally
advanced, curative radiotherapy with or without chemotherapy may be attempted. Patients with metastatic disease often
derive benefit from short duration palliative chemotherapy with cisplatinum combinations still being considered as standard
of care. Older and less fit patients can be treated with single agent chemotherapy with reasonable extension of life despite
a lower response rate. Radiotherapy is very useful for palliation of chest symptoms and bone metastases with minimal
inconvenience to patients as only short fractionation schedules are required. Several new “targeted” therapies are in
development with the promise of efficacy with minimal side-effects. Despite their promise, early results have been
disappointing and in the absence of definite proof, the use of these new drugs must be with caution. Rapid development in
this field promises a larger and more effective armamentarium in the future for lung cancer.
SYMPOSIUM 2A
SURGICAL MANAGEMENT OF LUNG CANCER AND AN UPDATE
MOHAMED EZANI TAIB
Department of Cardiothoracic Surgery, National Heart Institute, Kuala Lumpur, Malaysia
Lung cancer is the most common cancer in males in Malaysia and the 6th commonest cancer in females according to the
cancer registry, Malaysia 2002. Survival from lung cancer depends on cell type and stage of disease at presentation.
Preoperative assessment and investigation is crucial in providing the surgeon with adequate information about the suitability
of the candidate for curative surgery. Adhering to the guidelines of oncological surgery is imperative and important in securing
good outcomes and results for patients with lung cancer.
The survival of patients undergoing surgical resection of lung cancer is generally good for patients with stage I NSCLC
(80 – 85% T1 and 67 – 68% T2 at 5 years), Adjuvant therapy is this group is only useful for patients with positive resection
margins. For stage II NSCLC, the survival is about 40 – 50% at 5 years. Local recurrence rate is lower for patients given
adjuvant therapy however there is no difference in survival. In stage IIIA, the survival of patients depends on the N2 disease
and also proximity of the tumour to the carina. The overall survival rates are approximately between 20 – 50% at 5 years.
Adjuvant radiotherapy appears to reduce local recurrence but nor survival, however adjuvant chemotherapy seems to have
a modest survival benefit. Only in carefully selected patients with stage IIIB disease will be offered surgery and survival in this
group is only between 15 – 20% at 5 years.
Surgical treatment for non-resectable NSCLC tumours are mainly for symptomatic relieve such as in recurrent malignant
pleural effusion. There have been attempts to downgrade tumour staging by giving preoperative chemotherapy although
the evidence is still not very encouraging.
For small cell carcinoma (SCLC), surgery is not the primary modality of treatment and is only indicated in a small group
of patients.
In summary, the surgical management for lung cancer has not evolved much in the last 3 decades and survival for patients
with lung cancer is still dismal. It is hope that with better screening method, newer chemotherapy and radiotherapy
lung cancer can have a better outcome in the future.
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SYMPOSIUM 2B
TRACHEOMALACIA AND BRONCHOMALACIA
PETR POHUNEK
Division of Paediatric Respiratory Diseases, Paediatric Department, 2nd Medical School of
Charles University, Prague, Czech Republic
Instability of the airways may be a significant cause of obstructive ventilatory impairment. In children this is frequently caused
by primary immaturity of the airways. However, often tracheomalacia is associated with other problems, such as
tracheo-esophageal fistula, vascular compression or abnormal bronchial branching. Often tracheo/bronchomalacia can be
found as sequelae of bronchopulmonary dysplasia or even uncomplicated prematurity. Secondary dynamic airway
obstruction is mostly associated with chronic inflammation and may significantly contribute to clinical symptoms in patients
with cystic fibrosis, chronic bronchitis, primary ciliary dyskinesia and others.
In small children the obstructive symptoms caused by malatic airways may be difficult to differentiate from obstructive
symptoms in early bronchial asthma. Appropriate clinical differential diagnosis may provide a clue, in many cases direct
endoscopic assessment leads to final diagnosis. In such cases bronchoscopy must be performed with preserved spontaneous
breathing to allow for evaluation of dynamic airway obstruction. In cooperative children it is of major advantage to perform
bronchoscopy in mild sedation only and assess the airways under various regimens of breathing and breathing maneuvers.
The majority of small children with dynamic airway obstruction gradually recover with active conservative approach. In cases
associated with vascular compression surgical management may be considered. In most severe cases stenting may be
an option but there are still many difficulties associated with using tracheal or bronchial stents in children.
Surgical tracheoplasty may provide a permanent solution in cases where there is no chance of improvement.
SYMPOSIUM 2B
BRONCHIOLITIS OBLITERANS
PATRICK W K CHAN
Gleneagles Intan Medical Centre, Kuala Lumpur, Malaysia
Bronchiolitis Obliterans (BO) is a chronic respiratory inflammatory disorder that results in the obstruction and/or obliteration
of small airways. The development of BO follows an acute injury process such as infection ie adenovirus, Mycoplasma
pneumoniae, collagen vascular disease, drug hypersensitivity and toxic inhalation injuries. Post-infectious BO remains
the most common entity of this disorder seen in children in Malaysia. However, BO is of exceptional importance in paediatric
recipients of allogeneic bone marrow and lung transplant.
Children with BO have varying degrees of breathlessness, wheezing, cough and exertional intolerance. The hallmark of BO
is the persistence of respiratory symptoms after the initial acute respiratory event. Clinical findings are non-specific and
variable, largely dependent on the degree of airway obstruction. Although lung biopsy remains the most accurate method
to diagnose BO, less invasive investigations to assist in the diagnosis include high resolution computed tomography (HRCT)
of the chest, broncho-alveolar lavage cyto-chemistry and lung function studies. HRCT of the chest findings of
hypo-attenuation mosaic patterns, bronchial pruning, “tree in bud” appearance and differential segmental hyperinflation are
common in BO and may be considered diagnostic when present in combination with the clinical picture of BO. BO in lung
transplant recipients is indicative of graft dysfunction and early recognition is largely dependent on changes in lung function
namely a decline in FEF25 – 75.
There is no current definitive treatment for BO. Failure of treatment is due in part to the relatively late diagnosis of BO
at which time there is significant irreversible fibrosis and airway obliteration. Immunosupressive treatment using
methyprednisolone, hydroxchloroquine and cyclosporine for BO yielded variable results.
The prognosis of BO in the non-transplant population is difficult ascertain. The majority of children continue to have both
persistent respiratory symptoms and signs and abnormal lung function.
M A L A Y S I A N  T H O R A C I C  S O C I E T Y  –  8 t h A N N U A L  C O N G R E S S
26
SYMPOSIUM 2B
FLEXIBLE BRONCHOSCOPY – MY PERSONAL PRACTICE
PETR POHUNEK
Division of Paediatric Respiratory Diseases, Paediatric Department, 2nd Medical School of
Charles University, Prague, Czech Republic
Flexible bronchoscopy has developed into major instrumental diagnostic method in respiratory medicine. For more than
20 years the flexible bronchoscopy has replaced rigid technique in children and has been used in most diagnostic and even
in some therapeutic indications. The main advantage of flexible bronchoscopy is in the possibility to perform bronchoscopy
with full cooperation of the patient or at least under anesthesia with preserved spontaneous breathing. Also the reach of the
flexible bronchoscope into the peripheral airways is better than with the rigid instrument.
In the Czech Republic the pediatric flexible bronchoscopy has been introduced into practice by our service in 1989.
Since then several centers have been established and now there are 8 centers in the country where diagnostic flexible
bronchoscopy is routinely performed.
In the center for pediatric pulmonology and bronchology of the University Hospital of the 2nd Medical School of Charles
University in Prague we yearly perform about 300 diagnostic flexible bronchoscopies in children of all ages. The center
is equipped with all sizes of pediatric bronchoscopes and has full availability of complementary methods with a very good
laboratory background. The center serves as tertiary consult center for pediatric pulmonology and we therefore see patients
with various pathologies from all over the country. Our center also serves several neonatal ICUs in Prague even for emergency
bronchoscopies. There is also a large experience in use of flexible bronchoscopy in various pediatric obstructive airway
problems. The center serves also as a training center for pediatric flexible bronchoscopy within the postgradual curriculum
in pediatric pulmonology in the Czech Republic; however, it is open also to trainees from abroad.
SYMPOSIUM 3A
UNUSUAL CHEST XRAYS
PHILIP ENG
Department of Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore
Chest Radiology is the cornerstone of Respiratory Medicine. With advances in Chest Radiology, esp with rapidly improving
CT techniques, the question remains as to whether the plain film Chest Xray remains relevant in clinical practice today.
It is my opinion that the plain film Chest Xray remains a very important investigation that all Physicians must master.
Sadly, many of our trainees today rush into looking at the CT of the patient even before looking at the plain film or comparing
with previous films. In this presentation, I will show a few interesting Chest Xrays from my personal collection.
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SYMPOSIUM 3A
HRCT OF INTERSTITIAL LUNG DISEASES
GNANA KUMAR
Department of Radiology, University of Malaya, Malaysia
High Resolution Computed Tomography (HRCT) because of its excellent spatial resolution allows the visualization of the
lung parenchyma in thin slices (0.5 mm – 2 mm) at 10 mm intervals. This means that between 8 – 9.5 mm thickness of the
lung is not imaged between each slice. These scans do not require the administration of intravenous iodinated contrast media
and are typically done in full inspiration. When required prone or expiratory scans should be added.
With the advent of newer Multidetector CT scanners (4 – 64 slice per rotation) which are capable of imaging the entire thorax
in a single breath hold (less than 8 seconds) it is possible to acquire volumetric data of the entire lung(VHRCT).
In the evaluation of interstitial lung disease HRCT should be interpreted in conjunction with the clinical information and
other relevant tests. HRCT is more sensitive than a chest radiograph in detecting if the lung parenchyma is normal or not.
Among the different appearances seen on HRCT include nodules, linear/reticular abnormalities, ground-glass opacity,
consolidation and cystic (honeycomb) areas.
It also shows the extent of disease better and together with the clinical information can suggest the diagnosis and
therefore reduce the need of biopsy in some cases. It is useful in assessing the disease activity and response to treatment.
It can provide information as to which part of the lung to best biopsy.
SYMPOSIUM 3A
ROLE OF PET SCAN IN RESPIRATORY DISEASES
SU-YING LOW
Department of Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore
Positron emission tomography (PET) has been used as a research tool for many years. The advent of whole-body scanning
techniques and improved camera resolution has enabled its use to permeate into clinical practice, particularly oncology
imaging. PET scan in oncology is based on the principle that tumour cells have a much higher rate of glycolysis compared to
non-neoplastic cells. Based on these differences, PET is able to visualize and locate these malignant lesions. In respiratory
diseases, the use of PET is most established in the diagnosis of lung nodules and staging of non-small cell lung cancer
(NSCLC).
Studies evaluating PET in the diagnosis of solitary pulmonary nodules (SPN) 1 cm in diameter or more have found an average
sensitivity of 96.8% and specificity of 77.8%. When PET and conventional CT thorax have been compared for their accuracy
in determining nodal metastases in NSCLC, PET has universally been found to be superior to CT with an average sensitivity
of 88% and specificity of 91%. Whilst PET may have revolutionized physicians’ practices in this area of respiratory disease,
users must be wary of its pitfalls. Benign pulmonary lesions with high metabolic rates, including infectious and non-infectious
granulomatous lesions, are well known to cause false-positive PET scans. Similarly, false-negative PET scans are known
to occur in lesions with low metabolic activity such as bronchioloalveolar cell carcinoma and carcinoid tumours.
In respiratory oncology, PET scan has proven to be extremely valuable by providing a non-invasive method of selecting
patients for aggressive intervention without contributing to increased morbidity. However, limitations of this imaging modality
do not obviate the need for histological tissue confirmation. As the field of PET imaging evolves, other potential uses include
planning of radiotherapy, determination of prognosis, and development and clinical application of new radiotracers. The future
of PET remains promising and exciting.
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SYMPOSIUM 3B
CHILDHOOD ASTHMA
JESSIE A DE BRUYNE
Department of Paediatrics, University Malaya Medical Centre, Kuala Lumpur, Malaysia
The hygiene hypothesis and endotoxin exposure continue to be discussed with review of old and evaluation of new data.
The debate over the relationship of animals and asthma has been the most prolific. American studies now mirror European
studies showing a lower prevalence of asthma in children growing up on a farm. Owning a pet cat or dog and time
of exposure also influence the development of atopy and disease and more studies on pet exposure have been reported.
Apart from dose and timing of allergen exposure, sensitization and disease also depend on the genetic susceptibility of the
child and these important gene-environment interactions may allow us to develop specific methods of allergy prevention that
can be targeted at high-risk children rather than general recommendations for all.
Apart from the aetiology of asthma, genetics also had a showing in its treatment.
Pharmacogenetics opens up an interesting possibility of tailoring an individual’s therapy to his genetic make-up.
The relationship between specific genetic polymorphisms and response to beta-adrenergic agonists and leukotriene
modifiers may mean that more appropriate interventions are used for particular categories of patients depending on their
genetics.
One of the best-known and most impactful recent studies has been the GOAL (Gaining Optimal Asthma ControL) study
showing that 70% of patients with persistent asthma can achieve well-controlled status with combination therapy.
Although this was conducted in an adult population, extrapolation of the findings to the paediatric population has resulted in
a far greater use of fixed combination (steroid and long-acting bronchodilator) therapy in the management of asthma at
a lower level of severity than advocated in the guidelines. There has also been encouraging data on the use of sliding doses
of combination therapy.
The link between the upper airways and the lower airways continues to receive attention and it is increasingly accepted that
control of both parts of the airway is essential. Single agents can confer benefits to both (leukotriene antagonists,
newer anti-histamines) but adequate control of both may require more directed treatment.
The link between obesity and asthma has opened up another area where intervention may be beneficial. In the wake of the
modern epidemic of obesity, this has assumed greater importance.
The last year or so has seen on-going discussions and new material. Of one thing we can be sure – the story continues.
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SYMPOSIUM 3B
RESPIRATORY INFECTIONS
PETR POHUNEK
Division of Paediatric Respiratory Diseases, Paediatric Department, 2nd Medical School of
Charles University, Prague, Czech Republic
Respiratory infections still represent a major cause of morbidity, but also of mortality in both adults and children. In the
year 2004 the published papers concentrated mainly on several main topics that have been discussed already in the past
years.
One of the leading topics remains pneumonia and various aspects of its treatment. Epidemiological data have been discussed
and several papers have again pointed out the differences between assessing the situation in developing and developed
world. Trials with antibacterial vaccines that aim at reducing morbidity are ongoing and should bring not only direct clinical
benefit to the patients, but also some general information about epidemiology of pneumonia in the developing world.
Also some aspects of influenza vaccination around the world have been widely discussed.
One of the prominent issues is growing resistance of bacteria to the antibiotic therapy. These trends should be always
on mind of prescribing physicians and unnecessary overuse of antibiotics should be avoided.
Similarly as in the recent past years, the SARS still remains an important subject of many published papers. Thanks to the
scientific vigility of the colleagues who treated the cases during this epidemic and did not neglect the immediate systematic
collection of scientific data, we may now see several papers that evaluate many long term aspects of this severe epidemic
infection.
P L ENA RY L EC TURE  2
THE MANY FACES OF GERD – “ACID ASTHMA”
K L GOH
University of Malaya, Kuala Lumpur, Malaysia
Gastroesophageal reflux disease (GERD) has traditionally been thought to be a GI disease. We now understand that it has
in fact protean manifestations. Extra oesophageal or atypical manifestations are not uncommon and are important
presentations of the disease. GERD induced asthma is well recognized. The underlying mechanisms include macro and more
importantly micro aspiration and acid induced oesophago-bronchial reflex, which is neurally mediated by the vagus nerve.
The causal association of GERD in asthma is shown by the close association between the two diseases, the timing of asthma
episodes with acid reflux on pH monitoring and finally, by the response to treatment of asthma with potent acid suppression
therapy with proton-pump inhibitors (PPIs).
In a local study carried out at the University of Malaya Medical Centre, patients with “difficult-to-control” asthma as defined
by the GINA guidelines were treated with an 8-week course of standard dose PPIs. Patients with GERD experienced
a significant improvement in their asthma symptom score at the end of therapy, whereas the non-GERD patients who
received a similar course of PPIs experience no improvement in their asthma symptom score. This and other similar studies
underline the critical role of GERD in a subset of patients with “difficult -to-control” asthma.
GERD associated asthma patients often do not present with typical GERD symptoms such as heartburn and acid regurgitation.
Treatment with PPIs may need to be longer and with a higher dose of PPIs and response to treatment may not be as dramatic
as with classical GERD.
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SYMPOSIUM 4
MANAGEMENT OF MASSIVE HEMOPTYSIS
PHILIP ENG
Department of Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore
Massive hemoptysis is a common clinical problem which may result in admission of the patient to the Intensive Care Unit.
Aggressive and early management up front is of crucial importance. Management by a physician well trained in airway
control, ventilator management and bronchoscopy probably results in a favorable outcome. In this presentation,
I will highlight some very important pearls in the management of such a patient.
SYMPOSIUM 5
CHRONIC COUGH: HOW TO INVESTIGATE AND TREAT
ROSLINA A MANAP
Department of Medicine, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia
Chronic cough is a common clinical problem presenting to general practioners. Approximately 5 – 10% of new patients seen
in respiratory clinics are referred with an isolated chronic cough. Evaluation of chronic cough based on the “anatomic,
diagnostic” protocol originally is based on the view that most cases of nonasthmatic chronic cough are caused by
rhinosinusitus and/or gastro-oesophageal reflux. Others have advocated empirical treatment trials based on a best guess
of the underlying cause of the cough. The former approach often leads to an exhaustive and expensive number of
investigations, which, in any one patient, could include: spiromety; peak expiratory flow monitoring; a methacholine inhalation
test; induced sputum analysis; endoscopic examination of the upper and lower airways and upper gastrointestinal tract;
computerised tomography (CT) of the thorax and sinuses; and oesophageal manometry and pH monitoring. Abnormalities of
some of these tests are common in patients with airway disease of any kind; other tests, such as bronchoscopy and chest
CT scanning, have a very low yield in the absence of suggestive symptoms or chest radiographic changes.
Recently, a probability-based algorithm for the investigation and management of chronic cough has been advocated.
There is increasing recognition amongst clinicians with an interest in cough that an important minority of patients have no
obvious cause for their cough.
Specific treatment is directed at the underlying cause of cough and multiple or rarer causes that may not be immediately
evident need to be considered in cases of treatment failure.
SYMPOSIUM 5
PRIMARY PULMONARY HYPERTENSION: TREATMENT UPDATE
DAVID CHEW
Institut Jantung Negara, Kuala Lumpur, Malaysia
Primary pulmonary hypertension (PPH) is often diagnosed at a late stage and tends to progress relentlessly leading to
Right Ventricular (RV) failure and death.
Pulmonary hypertension can be due to a variety of causes, and these causes need to be excluded as some of them are
potentially treatable. PPH itself has multifactorial pathobiology including vasoconstriction, remodeling of the pulmonary
vessel wall, and thrombosis. Understanding of this pathogenesis has evolved over time resulting in improvement of treatment
outcomes. The management of PPH has evolved from vasodilators to treat vasoconstriction, to targeting the processes that
leads to endothelial proliferation and disease progression. These involve newer agents like prostanoids and endothelin
receptor antagonists.
Treatment of PPH can be divided into non pharmacologic and pharmacologic therapies.
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Non-pharmacological therapy
Non-pharmacological measures would include the use of supplemental oxygen, atrial septostomy and ultimately lung
or heart-lung transplantation. Transplantation is however limited by shortage of donors.
Pharmacologic Therapy
These can be divided into conventional or specific therapies. Conventional therapy:
1. Calcium antagonists. These are useful in patients who respond to vasodilators, but they constitute a minority of patients.
2. Anti failure therapy. These include diuretics, aldosterone antagonist and digoxin and are useful for symptom relief
in patients who have developed RV failure.
3. Anticoagulation with Warfarin.
Specific therapy:
1. Endothelin receptor antagonist e.g. Bosentan.
2. Prostanoids e.g. prostacycline (or epoprostenol), treprostinil, iloprost
3. Phospodiesterase inhibitors e.g. Sildenafil
The role of these therapies in patients with PPH will be discussed. One of the problems with specific drug therapy is the cost
of these drugs. Further understanding of the pathogenesis of this condition will help to improve the prognosis of this
devastating disease. It may be helpful for patients with PPH to be managed at specialized centers.
SYMPOSIUM 5
SARCOIDOSIS: ISSUES IN DIAGNOSIS AND TREATMENT
RICHARD LOH LI-CHER
Department of Medicine, International Medical University, Negeri Sembilan, Malaysia
Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating
granulomas, involving different organs in the body.
Intrathoracic (pulmonary and lymph node) involvement is frequent, up to more than 90% in some reported case series.
Despite the current evidence that sarcoidosis is found worldwide, the study of its epidemiology has been challenging.
The main reasons for this are the lack of consistency in case definition, variability in disease presentation and a lack of
sensitive and specific diagnostic tests, compounded by the scarcity of systematic epidemiologic studies. All these have led
to low rate of diagnosis as well as misdiagnosis of the disease. This is especially true in countries like ours where tuberculosis,
another granulomatous disease, features dominantly and empirical trial of corticosteroids alone in this setting can have
serious clinical consequences.
While corticosteroids remains the most effective treatment for sarcoidosis, decision to initiate and maintain treatment
is highly dependant on the severity of symptoms, nature of organ involved and likely course of the disease. Its indication
is normally clear if the disease is life-threatening or “sight”-threatening (ocular sarcoidosis). For asymptomatic pulmonary
sarcoidosis, a watch and wait approach is probably most appropriate. There have been other valuable alternatives tried in the
past few years. Example of such is leflunomide, an inhibitor of nucleotide synthesis, in treating chronic sarcoidosis.
Several immunosuppressive agents have also tried but they probably best viewed as ‘steroid-sparing’ agents.
Recently, International Consensus Statement1 recommendations regarding diagnosis and therapy reiterated that the
diagnosis of sarcoidosis should still be based on a compatible clinical and/or radiological picture, histological evidence of
noncaseating granulomas and exclusion of other diseases capable of producing a similar histological or clinical picture.
This lecture seeks to highlight some of these recommendations relevant to practicing physicians in Malaysian context and as
much as possible, published research work from Malaysia.
References:
1 Huninghake GW et al. ATS/ERS/WASOG Statement on Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-173
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FP  01
SERUM AND PLEURAL FLUID CANCER ANTIGEN 125 (CA125) LEVELS IN PATIENTS WITH
PLEURAL EFFUSIONS
SOON HIN HOW, CHONG KIN LIAM*, A. R JAMALLUDIN, ZAL AB RAHIM*
International Islamic University Malaysia, Kuantan, Pahang, Malaysia
*University of Malaya, Kuala Lumpur, Malaysia
OBJECTIVES
To determine the frequency of raised serum CA125 levels in patients with pleural effusions and to explore factors
affecting its elevation.
METHODS
All patients with pleural effusions admitted to the University Malaya Medical Centre from May 2001 to January 2002
were included in the study.
RESULTS
64 patients had benign effusions and 36 patients had malignant effusions (secondary to lung carcinoma in 22 patients and
other malignancies in 14 patients). There was no significant difference in age, gender, ethnicity and side of pleural effusion
between the benign and malignant groups. However, moderate to large effusions were more common in patients with
malignant effusions than in patients with benign effusions (66% vs 39%, p = 0.011).
Serum CA125 levels were above the cut-off level of 35U/dL in 78.1% and 83.3% of patients with benign and malignant
effusions, respectively (p = 0.532). The CA125 level was above 35U/dL in all malignant effusions and in 95.3% of benign
effusions (p = 0.187). The median CA125 levels were higher in the pleural fluid than in the serum in both the benign and
malignant groups. The serum CA125 levels were higher in female patients (p = 0.016), patients with moderate to large
effusions (p = 0.015), and those with malignant effusions (p = 0.001). There was a significant correlation between serum
CA125 level and pleural fluid CA125 level (r = 0.532, p < 0.001) but no correlation between serum CA125 level and pleural
fluid white blood count (r = – 0.092, p = 0.362), red cell count (r = – 0.082, p = 0.417) and LDH level (r = 0.062, p = 0.541).
CONCLUSIONS
Elevated CA125 levels in the serum and pleural fluid are common in patients with both benign and malignant pleural
effusions.
FP  02
CLINICAL CHARACTERISTICS OF FIRST ADMISSIONS AND READMISSIONS FOR ACUTE ASTHMA
NOOR HAFIZA N, NORZILA M Z, ZULKIFLI S Z*
Department of Paediatrics, Institut Pediatrik, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
*Department of Paediatrics, Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
INTRODUCTION
In Malaysia, the prevalence of childhood asthma has been reported to be 12% and asthma in children is still under-diagnosed
and often not managed optimally.
OBJECTIVES
To compare the characteristics of children with readmissions to hospital for acute exacerbation of asthma with those having
their first admission for asthma and to identify the differences between this two groups in terms of selected factors.
METHODS
This was a cross sectional study done within a time period of six months in Institut  Pediatrik, Hospital Kuala Lumpur.
It consisted of all children aged 1 – 12 years with their first ever asthma admission and children with at least one readmission
because of asthma exacerbation. Six potential risk factors for asthma admission were identified in the study. Statistical
analysis was done using Chi-square and t-test.
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RESULTS
A total of 196 children were enrolled in the study. There were 121 males (61.7%) and 75 females (38.3%) children.
When comparing first admission (FA) and readmission (RA) groups, there were significant differences in terms of age
of asthma diagnosis (p = 0.005), duration of asthma (p = 0.001), and pattern of asthma (p = 0.005). There were significant
differences in the type of treatment (p < 0.001), and type of inhalers prescribed (p = 0.006) between the two groups.
The mean asthma score was low in the two groups (p = 0.568). Both groups have the potential risk factors for future asthma
admission.
CONCLUSION
The study has showed that the RA group has better overall asthma management strategy as compared to the FA group.
FP  03
PREDICTORS OF POSITIVE BLOOD CULTURES IN PATIENTS WITH COMMUNITY ACQUIRED
PNEUMONIA
Y K PANG, C K LIAM, C H LEOW, P SHYAMALA, AB ZAL
Department of Medicine, University Malaya Medical Centre (UMMC), Faculty of Medicine,
University of Malaya, Kuala Lumpur, Malaysia
OBJECTIVE
To define the clinical features and laboratory findings on admission predicting bacteraemia in patients hospitalised
for community acquired pneumonia (CAP).
METHODS
A prospective study on consecutive non-immunocompromised patients aged 12 years and above admitted to the medical
wards of UMMC for CAP.
RESULTS
During the period of study, a total of 352 patients with a mean (± SD) age of 56 (± 20) (range, 13 to 97) years were admitted
for CAP. The blood culture of 27 (7.7%) patients was positive. The pathogens isolated from the blood included
Klebsiella pneumoniae in 10 patients; Streptococcus pneumoniae in 8; Staphylococcus aureus in 6; and Haemophilus
influenzae, Escherichia coli and Acinetobacter species in one patient each. Multivariate analysis showed that the clinical
features of CAP that were independently predictive of positive blood culture were an admission heart rate above 100/min
(odds ratio, 2.64; 95% confidence interval, 1.04 to 6.74; P = 0.042) and admission serum creatinine greater than 130 µmol/L
(OR, 3.09; 95% CI, 1.24 to 7.72; P = 0.016). Prior antibiotic therapy within 7 days before hospitalization was negatively
associated with positive blood culture (OR, 0.24; 95% CI, 0.09 to 0.63, P = 0.004).
CONCLUSIONS
Tachycardia above 100 per minute and raised serum creatinine on admission were predictors of positive blood cultures
in patients hospitalized for CAP. Blood cultures were less likely to be positive in patients who had received prior antibiotic
therapy within 7 days of hospital admission.
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FP  04
POST HOC ANALYSIS OF COST BENEFIT OF USING ETHYL CHLORIDE SPRAY VS 2% LIGNOCAINE
TO REDUCE PAIN ASSOCIATED WITH RADIAL ARTERY PUNCTURE IN
HOSPITAL UNIVERSITI KEBANGSAAN MALAYSIA (HUKM)
MOHD ZAMRI ABDUL RAHMAN, ROSLAN HARUN, RIZAL ABDUL MANAF*, FAUZI MOHD ANSHAR
Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia
*Department of Public Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Malaysia
INTRODUCTION
Radial artery puncture for arterial blood gas sampling produces moderate pain which can be reduced by administering a local
anaesthetic agent. We performed a study showing that ethyl chloride spray is as efficacious as subcutaneous infiltration
of 2% lignocaine in reducing the pain (submitted for publication). A post hoc analysis was done to compare the cost of using
each local anaesthetic agent.
OBJECTIVES
To compare the cost of radial artery puncture using the two local anaesthetic agents.
METHODOLOGY
A group of adult patients requiring arterial blood gas sampling in HUKM were randomized into two groups (2% lignocaine
infiltration and ethyl chloride spray prior to radial artery puncture). A visual analogue score (VAS) was used to assess pain.
The cost for each group was calculated based on HUKM cost of procurement and was compared.
RESULTS
Sixty six patients entered the study (n = 33 each group). The median VAS for both agents was 1.1 cm but interquartile range
for ethyl chloride and 2% lignocaine was 1.7 cm and 1.4 cm respectively. The difference was not significant, p = 0.953.
The cost to perform radial artery puncture for ethyl chloride and 2% lignocaine was RM0.24 and RM0.75 respectively
(ethyl chloride was 68% cheaper)
CONCLUSION
Both agents are equally effective in reducing pain but using ethyl chloride spray would produce greater cost saving.
FP  05
SURGERY FOR EMPYEMA THORACIS: THE NORTHEN REGON EXPERIENCE
KO CHUNG SEN
Consultant Cardiothoracic Surgeon, Ipoh Specialist Hospital, Ipoh, Perak, Malaysia
BACKGROUND
Empyema thoracis remains a serious thoracic infection, with mortality as high as 20% reported despite modern treatment.
OBJECTIVE
To review the management and outcome of patients with empyema thoracis treated surgically.
METHODOLOGY
Hospital records of all patients operated for empyema thoracis between were reviewed retrospectively.
A total of 35 patients were evaluated.
RESULTS
85.7% of patients were males 30/35. The mean age is 33.5 (1.5 – 64 years). Ten patients were from the paediatric
age group 10/35 (28.6%). The aetiology of empyema was tuberculosis in 9 patients 9/35 (25.7%) and in another 26 patients
recorded to be pyogenic in origin although cultures were positive in only 7 (26.9%) patients. Undiagnosed carcinoma were
found in two patients (5.7%) and tuberculosis in 4 (11.4%) patients. Rib resection and open drainage was performed in
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5 patients (14.3%) while the rest underwent thoracotomy and decortication. Thoracoplasty was required in 4 patients (11.4%)
who had tuberculosis. There was a single mortality (2.8%) in the patient who had unexpected malignancy. The rest of the
patients were discharged well.
CONCLUSION
Empyema thoracis can be managed with good outcome as well as low morbidity and mortality, even in cases requiring
thoracoplasty. Management of tuberculous empyema remains a formidable challenge necessitating thoracoplasty in some
cases. Significant number of patients had unsuspected tuberculosis or malignancy .
FP  06
DRUG INDUCED HEPATITIS (DIH) FROM 1ST LINE ANTITUBERCULOSIS DRUGS AMONG PATIENTS
TREATED FOR ACTIVE TUBERCULOSIS – RESPIRATORY UNIT, PENANG HOSPITAL 2004 
ONG C K, TAN W C*, ABDUL RAZAK M*
Respiratory Unit, Penang Hospital, Penang, Malaysia
*Department of Dermatology, Penang Hospital, Penang, Malaysia
INTRODUCTION
A major adverse reaction to one of the first line antituberculous drugs, which results in discontinuation of that drug,
has several implications. There may be considerable morbidity, even mortality, particularly with drug induced hepatitis (DIH).
Identification of patients with risk factors will facilitate monitoring for hepatotoxicity.
OBJECTIVES
• To determine drug(s) that commonly cause DIH in patients treated for active TB.
• To identify the common manifestation of DIH in patients treated for active TB
• To determine the role of various risk factors in the development of DIH in patients receiving anti-TB therapy
METHODOLOGY
This retrospective review looked at the cases of adult active TB treated in Respiratory Unit, Penang Hospital
from January 2004 to December 2004. DIH is defined as any rise in ALT > pre-treatment level or a rise in total bilirubin
> 17 micromol/L irrespective of symptoms. The information were obtained from patient’s medical report, TB booklet and
in-patient record (if they were admitted before).
RESULTS
381 patients treated for active TB were recruited for this study. 23 patients (7 females; 16 males) developed DIH (6.0%).
11 of 23 patients were Chinese, Malay 9 patients and Indian 3 patients. 73.9% of DIH occurred in the age group of
35 – 59 years. Pyrazinamide remains the commonest offending drug (47.8%), followed by rifampicin (30.5%) and isoniazid
(21.7%). No DIH was observed with ethambutol or streptomycin. In our observation, we noted that all the cases with
cholestatic hepatitis picture were caused by rifampicin. Pyrazinamide usually caused mixed picture of hepatitis or isolated
raise in liver transaminases (ALT). Patients with DIH commonly presented with nausea (69.6%), jaundice (65.2%), vomiting
(34.8%), anorexia (26.1%), and abdominal pain (8.7%). 3 patients were asymptomatic. DIH usually occur after 1 week
of treatment but is still possible even after 2 months of treatment. Various major risk factors were identified, which include
pre-existing liver disease like hepatitis / alcoholic liver disease (30.4%), alcohol consumption (21.7%), polypharmacy (21.7%)
and HIV infection (17.4%). 13 (56.5%) patients with DIH had low albumin level at diagnosis. Of 7 patients with pre-existing
liver diseases, 6 of them were Hepatitis C positive (All of them were IVDU).
CONCLUSION
The incidence of DIH was higher with pyrazinamide, was associated with male sex, age 35 and above, HIV infection and
those with pre-existing liver disease.
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EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED THERAPY WITH GEFITINIB IN
LOCALLY ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER
LIAM CHONG KIN
Department of Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia
OBJECTIVE
To describe the efficacy of monotherapy with the orally active, selective epidermal growth factor receptor-tyrosine kinase
inhibitor, gefitinib in patients with locally advanced and metastatic non-small cell lung cancer (NSCLC).
PATIENTS AND METHODS
Patients with progressive locally advanced or metastatic NSCLC previously treated with systemic cytotoxic chemotherapy
and/or radiotherapy or who declined chemotherapy or were medically not suitable for cytotoxic chemotherapy.
RESULTS
24 patients (13 male, 11 female) (16 smokers, 8 never smokers) with a median age of 56 (range, 35 – 79 years);
20 with adenocarcinoma (3 bronchioloalveolar subtype), 3 squamous cell carcinoma and one undifferentiated NSCLC,
received monotherapy with gefitinib 250 mg orally once daily until disease progression. At the time of starting gefitinib, one,
3 and 20 patients had stage IIIa, IIIb and IV disease, respectively. Of 18 patients who had failed cytotoxic chemotherapy,
one had radiotherapy to the primary tumour and two had radiotherapy to their brain metastases. Two of the
6 chemotherapy-naïve patients received radiotherapy to the primary tumours. The WHO performance status at the time
of starting gefitinib was 1, 2, 3 and 4 in 16, 5, 2 and 1 patient, respectively. The median interval from the diagnosis of NSCLC
to the commencement of gefitinib was 18.5 (range, 4 – 177) weeks.
The disease was controlled in 15 patients (62.5%). There was a reduction in the size of the primary and/or metastatic tumours
in 11 patients (partial response) (45.8%) and 4 patients (16.7%) had stable disease. The response rate was significantly higher
in those who never smoked (90.9%) compared to that of smokers (46.2%) [OR (95% CI), 11.67 (1.14 – 119.54)] (p = 0.033).
All symptomatic patients whose disease was controlled had symptom improvement. The median time to symptom
improvement was 2 (range, 0.5 – 6) weeks. The median progression-free survival time was: patients with PR = 60.0 wks
(range, 7 – 130; 25 centile, 75 centile, 10, 91) and patients with SD = 36 wks (range, 7 – 52; 25centile, 75centile, 13.8, 48.5).
The disease remained under control with gefitinib monotherapy for at least a year (range, 52 to 130 weeks) in 7 patients.
Adverse effects were generally mild and consisted of acne, dry skin, pruritic rash and diarrhoea in 7, 8, 3 and 3 patients,
respectively.
CONCLUSIONS
When given alone, gefitinib shows significant antitumour activity in selected patients with advanced NSCLC. Adverse effects
of the drug are generally mild.
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DIFFERENCES IN CLINICOPATHOLOGICAL FEATURES OF NON-SMALL CELL LUNG CANCER
IN SMOKERS AND NEVER SMOKERS
LIAM CHONG KIN
Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia
OBJECTIVE
To determine the differences in the clinicopathological features of non-small cell lung cancer (NSCLC) in smokers and
never smokers.
PATIENTS AND METHODS
Consecutive patients with NSCLC confirmed by histology and/or cytology at the University Malaya Medical Centre,
Kuala Lumpur, Malaysia.
RESULTS
Of 428 patients with NSCLC, 101 patients (23.6%) were never smokers, 120 (28.2%) were females and 85.5% had locally
advanced (stage III) or metastatic (stage IV) disease. 74.3% of the never smokers and 13.8% of the smokers were female
(OR, 18.08; 95% CI, 10.47 to 31.20; p < 0.001). Never smokers were diagnosed with NSCLC at a younger age [mean age (±SD),
55.6 (±15.1) years] than the smokers [mean age (±SD), 61.7 (±10.7) years] (mean age difference, – 6.1 years; 95% CI,
– 3.4 to – 8.7; p < 0.001). Adenocarcinoma was the most common cell type in both smokers and never smokers. However,
the percentage of never smokers with adenocarcinoma (87.1%) was significantly higher than that of smokers with
adenocarcinoma (50.2%) (OR, 6.73; 95% CI, 3.61 to 12.52; p < 0.001). Although a higher percentage of the smokers had early
stage (I or II) disease compared to the never smokers (16.2% versus 8.9%), the difference was not statistically significant
(OR, 1.98; 95% CI, 0.94 to 4.17; p = 0.069). A higher percentage of never smokers (35.6%) than smokers (24.5%) had poorer
WHO performance status of 3 or 4 at the time of diagnosis (OR, 1.71; 95% CI, 1.06 to 2.76; p = 0.027).
CONCLUSIONS
Compared to smokers, never smokers who have NSCLC are more likely to be female and younger and to have
adenocarcinoma and poorer performance status at the time of diagnosis.
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BRONCHOSCOPIC LASER THERAPY FOR ADENOID CYSTIC CARCINOMA OF TRACHEA:
A CASE REPORT
ZAL AB RAHIM, LIAM CHONG KIN
Division of Respiratory Medicine, Department of Medicine, University Malaya Medical Centre,
Kuala Lumpur, Malaysia
OBJECTIVE
To describe a patient with adenoid cystic carcinoma of the trachea who underwent Nd-YAG laser therapy through flexible
bronchoscopy.
CASE REPORT
The patient is a 40-year-old Chinese woman, a never smoker, who was referred for further management of a dry cough
which started in July 2004 and noisy breathing with shortness of breath since October 2004. She was earlier treated
for bronchial asthma by the referring medical centre without improvement. There was no haemoptysis or constitutional
symptoms. Flexible bronchoscopy in that centre 2 weeks prior to her presentation at our hospital revealed an endotracheal
tumour, biopsy of which showed adenoid cystic carcinoma. Computed tomography revealed a circumferential mass in the
wall of the trachea which caused narrowing of the lumen. Her flow-volume loop was consistent with a variable intrathoracic
upper airway obstruction. Bronchoscopy examination revealed a large broad-based polypoidal tumour on the posterior wall
of the trachea with a vertical extent of 3.5 cm starting from 2.5 cm below the vocal cords. In addition, there were multiple
nodular lesions on the anterior wall of the trachea at the same level. The obstruction of the lumen was 80% at the narrowest
segment. The tumour was deemed too extensive for surgical resection. She had 2 episodes of near fatal respiratory arrest
due to retained airway secretions during her hospital stay. Laser therapy was administered to the tracheal wall tumour
fortnightly with 3371, 1617, 834, 2100, 620 and 905 joules during the 6 sessions, respectively. Argon plasma coagulation
therapy was administered to the anterior tracheal wall nodules. The tracheal obstruction was reduced to less than 10%
at the narrowest segment and her cough, dyspnoea and stridor had resolved.
CONCLUSION
Although not curative, Nd-YAG laser therapy via flexible bronchoscopy is very effective in relieving obstruction of the
trachea and distressing respiratory symptoms in this patient with unresectable exophytic malignant tracheal wall tumour.
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OFF PUMP TRACHEAL AND CARINAL TUMOUR RESECTION 
KO CHUNG SEN 
Consultant Cardiothoracic Surgeon, Ipoh Specislist Hospital, Ipoh, Perak, Malaysia
Tracheal and carinal tumours were once considered inoperable. Resection can now be performed safely without the need
for cardiopulmonary bypass with improved technique. Two cases of lower tracheal and carinal tumours were resected
successfully with primary anastomosis.
Right thoracotomy was performed in both cases. Bulky double lumen tube was not feasible with the presence of the
obstructing lesion. The left main bronchus was selectively intubated with a long oro-tracheal tube to collapse the right lung.
The right chest was then opened via the 4th inter-costal space. The trachea was dissected and tumour confirmed respectable.
The oro-tracheal tube was withdrawn proximal to the tumour and the trachea divided. The left lung was then directly
intubated trans-thoracically. The tumour segment was then excised with primary anastomosis. Posterior  half of the sutures
were placed and tied. The trans-thoracic ET tube was removed and the oro-tracheal tube advanced across the anastomosis
and the rest of the sutures placed and tied. Drains were inserted and the chest closed.
Immediate extubation on table was achieved in both cases with the use of inhalational anaesthetics and short acting muscle
relaxants.
Both cases were discharged home within 10 days without complication.
CONCLUSIONS
Localized tracheal and carinal tumours are amenable to complete surgical resection and long term survival.
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SECOND LINE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA WITH PEMETREXED
(ALIMTA), A MULTITARGETED ANTIFOLATE AGENT: A REPORT OF TWO CASES
ZAL AB RAHIM, LIAM CHONG KIN, PANG YONG KEK, LEOW CHAI HOOI
Division of Respiratory Medicine, Department of Medicine, University Malaya Medical Centre,
Kuala Lumpur, Malaysia
OBJECTIVE
To report our experience with using a new multitargeted antifolate agent, pemetrexed (Alimta) in the treatment of malignant
pleural mesothelioma in Malaysian patients.
CASE REPORT
We report, the first two patients with malignant pleural mesothelioma in Malaysia, we believe, who were treated with the
combination of pemetrexed/cisplatin. Both patients had progressive disease following 2 cycles of first-line cytotoxic
chemotherapy with gemcitabine/cisplatin. Second-line chemotherapy was commenced with pemetrexed at 500 mg/m2
administered as an intravenous infusion over 10 minutes followed 30 minutes later by cisplatin intravenous infusion at
75 mg/m2 over 2 hours on the first day of each 21-day cycle. The premedication regimen consisted of (i) intramuscular vitamin
B12 1000µg starting one week before the first dose of pemetrexed and repeated every 9 weeks; (ii) oral folic acid
supplementation at 1000 µg daily beginning 1 week before the first chemotherapy doses, continuing throughout treatment
and for 3 weeks post-treatment; and (iii) oral dexamethasone at 4 mg twice daily taken the day before, the day of, and the
day after the administration of pemetrexed.
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Impressive symptomatic and functional improvements as well as some radiological response were observed after the first
2 cycles. However, the disease in both patients progressed despite 4 cycles of pemetrexed/cisplatin. Hence, chemotherapy
was discontinued. Both patients had grade 2 anaemia requiring blood transfusion pre-chemotherapy. One patient had grade
2 stomatitis which resolved with symptomatic treatment.
CONCLUSIONS
Malignant pleural mesothelioma is generally resistant to conventional cytotoxic chemotherapy. Pemetrexed combined with
platinum is an active regimen which confers symptomatic and radiological response accompanied by tolerable side effects
with appropriate premedication.
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SENDING CHILDREN HOME WITH HOME VENTILATION: THE MALAYSIAN EXPERIENCE
NORZILA MZ, ASIAH I*, RUSANIDA A, HASNIAH AL, KHOO T B*, CHOY Y S**
Respiratory Unit, Paediatric Department, Institute Paediatrik, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
*Neurology Unit, Paediatric Department, Institute Paediatrik, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
**Genetic Unit, Paediatric Department, Institute Paediatrik, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
INTRODUCTION
There is an increasing population of children with chronic respiratory failure due to underlying conditions such as failure
of ventilatory control, chest wall abnormalities and muscle disorders.
METHODS
We conduct a retrospective review of all children that were ventilated at home. These children were referred to the
Respiratory Unit for a respiratory evaluation including sleep disordered breathing (SDB). Polysomnography were performed
on all these patients. Ventilation was initiated using pressure pres set ventilator assist mode. (BIPAP–RESMED).
RESULTS
From 2001 – 2004, a total of 17 patients were discharged home on BIPAP support.
The median age of starting BIPAP support was 5 years old (0.3 – 11 years). Thirteen children were males with an ethnic
distribution predominantly Malays.
Eight children required full time ventilation while the remaining eight children required nocturnal support during sleep.
One patient died due to progressive disease.
Six patients were ventilated via tracheostomy while the remaining 11 patients were ventilated non-invasively via nasal mask
as interface.
Prior to the initiation of the BIPAP support, these patients had respiratory failure type 2. With BIPAP, there was statistically
significant improvement in pH (p = 0.008), and reduction in pC02 (p = 0.028) and improvement in Sao2 (p = 0.056).
CONCLUSION
There is an increasing trend of ventilating children at home. Non-invasive ventilation is a mode of ventilating children at home.
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COMPLIANCE AND SIDE-EFFECTS OF CPAP AFTER AUTOSET TITRATION
M R NORHAYA, A K SIMONDS
Department of Medicine, Hospital Kuala Terengganu, Kuala Terengganu, Terengganu, Malaysia
INTRODUCTION
Continuous positive airway pressure (CPAP) is standard treatment for patients with obstructive sleep apnoea (OSA). It is not
however without side-effects, which may affect the compliance with therapy. This study was undertaken to determine the
prevalence of CPAP side-effects and their impact on patient compliance.
METHODOLOGY
Patients with OSA who received an auto-CPAP titration study were selected at random and studied prospectively. They were
required to complete a questionnaire on CPAP use and side-effects.
RESULTS
Twenty-two patients completed the questionnaire. Only one patient was found to be markedly non-compliant with therapy.
Of those who complied with CPAP, side effects were generally mild and well tolerated.
CONCLUSIONS
In this group of mild to severe OSA patients CPAP following autoset tiration was effective treatment and was associated with
few side-effects.
Keywords: CPAP, auto CPAP, side-effects, compliance
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OXYGEN THERAPY IN THE ACUTE HOSPITAL SETTING – AN AUDIT
A FAIZAL, M R NORHAYA, A HASNAN, I NOR ISMARUDI
Department of Medicine, Hospial Kuala Terengganu, Kuala Terengganu, Terengganu, Malaysia
INTRODUCTION
The prescription and use of oxygen in hospital can be haphazard. We decided to investigate further and write
recommendations for the use of oxygen in our Hospital.
OBJECTIVES
• Assessment of knowledge of doctors and paramedics in the use of oxygen
• To write recommendations for the use of oxygen in our hospital
METHODOLOGY
Prescription of oxygen by doctors and paramedics in the Accident and Emergency (A & E), Coronary Care Unit (CCU) and
the active medical wards were studied. This is done by requesting them to fill up prepared questionnaires (Appendix 1)
RESULTS
Ninety eight staff participated.
What percentage oxygen would you give in a cardiac/respiratory arrest?
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82.6% would give 60 – 100%, 5.1% would give 40 – 60%, 2.0 % would give 28 – 40% while 10% do not know what to give.
What percentage of oxygen would you give in a chronic obstructive pulmonary disease (COPD) patient with acute
exacerbation?
1% did not know, 16.3% would give oxygen depending on the situation, 63.2% would give 28 – 40%, 19.4% would give
40 – 60%
What percentage of oxygen would you give in acute exacerbation of asthma?
10.2% would give 100% or more, 31.63% would give 60 – 100%, 25.51% would give 40 – 60% 5.9% would give 28 – 40%,
while the rest were unsure.
CONCLUSIONS
Oxygen is a drug and should be prescribed with care
Specific prescription charts may improve the prescription of oxygen
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CONGENITAL BILATERAL VOCAL CORD PARALYSIS – A CASE SERIES
AL HASNIAH, K ASIAH*, D MARIANA*, A RUS ANIDA*, MZ NORZILA*, S SAHRIR**
Department of Paediatrics, Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
*Respiratory Unit, Paediatric Institute, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
**ENT Department, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Congenital upper airway obstruction is a relatively rare but important cause of major respiratory problems in the neonatal
period. Vocal cord paralysis is the second most common cause of congenital airway obstruction presenting with neonatal
stridor and is often the reason for the failure of neonates to wean from the respiratory support.
A retrospective analysis of medical record review was conducted. There were seven paediatric patients diagnosed with
bilateral vocal fold paralysis for the past 3 years, of which five of them were recently diagnosed. All patients underwent
flexible with/without rigid bronchoscopes to confirm the diagnosis.
This case series highlight our experience in managing the problem of bilateral vocal fold paralysis in paediatric population,
with particular emphasis on their clinical presentations, associated complications and other upper and lower airway
abnormalities as well as the management options and outcome of these patients.
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USE OF NASAL CPAP IN OBESE CHILDREN WITH OBSTRUCTIVE SLEEP APNEA
AL HASNIAH, K ASIAH*, A RUS ANIDA*, MZ NORZILA*
Department of Paediatrics, Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
*Respiratory Unit, Department of Paediatrics, Paediatric Institute, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
INTRODUCTION
Obesity is a significant risk factor for obstructive sleep apnea syndrome (OSAS). Over the last decade, nasal continuous
positive airway pressure (CPAP) has been increasingly used in children with OSAS as a successful alternative to upper airway
surgery or tracheotomy.
OBJECTIVE
To report our experience in treating obese children with OSAS with nasal CPAP, in Paediatric Respiratory Unit,
Hospital Kuala Lumpur, over the last two years.
METHODS
A retrospective analysis of medical record reviews was conducted. Seventeen obese children with OSA were prescribed
nasal CPAP from February 2002 to August 2004. Three patients were excluded as their medical records were missing.
The diagnosis of OSA was confirmed by an overnight polysomnography.
RESULTS
The median age of 14 children was 8.5 years. Their mean body mass index was 34.4 (range 27.6 – 42.0). The commonest
symptoms were snoring and night awakening (100%), difficulty in breathing during sleep (92.9%) and daytime
hypersomnolence (85.7%). All patients had significant respiratory events with Respiratory Disturbances Index (RDI)
> 5 (median 13.4) with Obstructive Apnea Index (OAI) > 1 (median 4.4). All patients experience improvement in their clinical
symptoms. Two patients were managed to wean off nasal CPAP after adenotonsillectomy. The rest are still on CPAP,
most likely due to increasing weight.
CONCLUSION
Nasal CPAP is feasible and well-tolerated in obese children with OSAS. The treatment of OSAS by tonsillectomy
and/or adenoidectomy in obese children leads to clinical improvement of the obstructive symptoms, but will not help in
weight reduction.
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PERCEPTION OF THE ISLAMIC RULING ON SMOKING AMONG MUSLIMS
C A SHAHRIN TARMIZI , S H HOW, A M PUTERI MELOR
Department of Medicine, Faculty of Medicine, International Islamic University Malaysia (IIUM),
Kuantan, Pahang, Malaysia
INTRODUCTION
Smoking is still prevalent among muslims in this country despite the public knowledge that some muslim religious leaders
regard smoking as haram.
OBJECTIVES
Our objective was to determine whether there are differences of perception about the Islamic ruling of smoking between
muslim smokers and muslim non-smokers.
METHODS
A questionnaire survey was carried out among the public who attended the IIUM Faculty of Medicine open day in Kuantan,
Pahang on 12 – 13 June 2004.
RESULTS
Seventy four muslims participated in the survey. 46 (63%) were smokers (including 1 ex-smokers) and 28 (37%) were
non–smokers. There was no statistical difference between the knowledge of smoking-related illnesses between smokers and
non-smokers. Smokers and non-smokers showed no difference in knowing that certain religious scholars verdict smoking
as haram. (58% vs 42% respectively, p > 0.05). Only 6.7% of smokers perceive smoking as haram compared to 48% of
non-smokers (p < 0.001). 82% of smokers viewed smoking as makruh compared to 40% of non-smokers (p < 0.001).
36% of non-smokers perceive smoking is haram as the main reason for not smoking and 54% because of the danger of
smoking to health.
CONCLUSIONS
Perception that smoking is haram among smokers is still poor, which may be one of the main reasons contributing to the
high prevalence of smoking in our Muslim society.
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CLINICAL OUTCOMES AND PATIENT SATISFACTION WITH A PIONEER OUTPATIENT PULMONARY
REHABILITATION PROGRAM IN HOSPITAL UNIVERSITY KEBANGSAAN MALAYSIA (HUKM)
FAUZI MOHD ANSHAR, ROSLINA ABDUL MANAP, RIZA SHAROM A RAZAK*,
KATIJJAHBE M ALI*, AYIESAH RAMLI*
Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
*Department of Medical Rehabilitation, Faculty of Medicine, Universiti Kebangsaan Malaysia,
Kuala Lumpur, Malaysia
INTRODUCTION
Pulmonary rehabilitation (PR) is a beneficial multidisciplinary program for patients with chronic respiratory diseases.
It was started in HUKM in March 2004. HUKM is the pioneer in Malaysia in PR and the service is offered as an eight-week
outpatient program.
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OBJECTIVES
To assess patients’ breathlessness and satisfaction with the HUKM PR program.
METHODOLOGY
Patients who completed their PR program from March 2004 until April 2005 answered self-administered questionnaires.
Data was collected on gender, age, race and underlying diagnoses. We asked about breathlessness before and after the
program and their overall satisfaction.
RESULTS
Within the period, 18 patients (16 males and 2 females) entered and completed the program. Response rate was 17/18 (94%).
Mean age 62 years (age range 46 – 80). Majority was Malay (14/17, 82%), followed by Indians (2/17, 12%) and others
(Iban 1/17, 6%). COPD predominates (15/17, 88%); other diagnoses are lung fibrosis (1/17, 6%) and bronchiectasis (1/17, 6%).
More than half (11/17, 65%) found it hard to exercise initially but all reported improvement at the end of week 8.
Majority (15/17, 88%) were less breathless at the end of the programme. All patients reported satisfaction with the service.
CONCLUSION
PR is beneficial for patients with chronic respiratory impairment. Our patients were satisfied with our service.
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METABOLIC ALKALOSIS IS A COMMON MANIFESTATION OF CYSTIC FIBROSIS
IN THE LOCAL POPULATION
ANNA MARIE NATHAN, JESSIE A DE BRUYNE
Respiratory Unit, Department of Paediatrics, University Malaya Medical Centre, Kuala Lumpur, Malaysia
Cystic fibrosis is an uncommon disease in the Asian population. Patients usually present with respiratory and gastro-intestinal
manifestations and, although metabolic alkalosis is a well-recognised occurrence, it does not appear to be a typical feature
in the European population. We discuss a child who presented as a diagnostic dilemma with recurrent episodes of
hyponatraemic, hypokalaemic metabolic acidosis and apparently minimal respiratory and gastro-intestinal symptoms.
This patient will be contrasted with two others, one of whom presented with primarily respiratory symptoms and the other
who presented with primarily gastro-intestinal symptoms. However, both these patients also experienced significant
electrolyte abnormalities – the former displaying a pronounced pseudo-Bartter phenomenon associated with the respiratory
exacerbations and the other requiring potassium supplements for unexplained hypokalemia before the diagnosis was made.
It would appear that hypokalemic metabolic alkalosis is a consistent feature in these patients and is seen more commonly
in local patients with cystic fibrosis than in European patients. This is likely to be due partially to the hot tropical climate but
may also signify different expressions of the disease.
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DERMOGRAPHIC DATA OF HIV INFECTED INMATES OF A REHABILITATION CENTRE
A FAIZAL, M R NORHAYA, A R ARZANA, A A ZAHARI, Y ROSNAH, A KALSOM
Department of Medicine, Hospital Kuala Terengganu, Kuala Terengganu, Terengganu, Malaysia
INTRODUCTION
All inmates of drug rehabilitation centres are screened for HIV. The dermographic data of those infected with the virus were
studied in a local rehabilitation centre.
OBJECTIVES
• To find out the  dermographic distribution of the inmates
• To find out the risk behaviour resulting in HIV infection
• To look into factors contributing to HIV infection in these inmates
METHODOLOGY
After getting a written consent, HIV infected inmates were interviewed individually by trained staff using prepared
questionnaires.
RESULTS
One hundred inmates were interviewed. All of them were males age ranging from 21 to 44 years old. One was a Chinese,
another Indian while the rest were Malays. Seventy percent were still single while 20% were married and the last 10% were
divorced. None had tertiary education, 2% never went to school while 80% had secondary school education. Twenty-three
percent were unemployed, 12% were fishermen, 39% were self-employed, 10% owned small businesses, while only 1% had
a fixed occupation. Ninety percent were smokers where 82 percent of these smoked more than 20 cigarettes per day and
all acquired the addiction to nicotine through friends. Seventy-five percent acquired HIV via infected shared needles,
20% sexually while the rest declined to state their risk behavior.
CONCLUSIONS
The HIV infected individuals belonged to a young age group.
More than a third are injecting drug users.
They did not have a high level of education
Most did not earn a fixed income
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PULMONARY MELIOIDOSIS: A REVIEW OF 70 CASES FROM PAHANG
S H HOW, HOI POH TEE*, A R JAMALLUDIN, A SHAH, Y RATHOR, SAPARI SATWI*
Kulliyyah of Medicine, International Islamic University Malaysia, Kuantan, Pahang, Malaysia
*Department of Internal Medicine,Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia
OBJECTIVE
To study clinical features, radiological findings and clinical outcome of patients with pulmonary melioiodsis.
METHODOLOGY
Retrospective study on adult patients with pulmonary melioidosis in Pahang from January 2000 to June 2003 with positive
culture for B. pseudomallei.
RESULT
There were 59 Malays (84.2%), 7 Chinese (10.0%), 2 Indians (2.9%) and 2 aborigines (2.9%). Most patients were between
40 to 60 years of age and the mean age was 53 ±13 years. Commonest predisposing factor was diabetes mellitus (82.8%).
Fever was the commonest presentation (96%) followed by cough (75%) but only one had haemoptysis. Majority of patients
presented with isolated pneumonia (78.6%), the remaining had multiple organ involvement. There was no pathognomonic
feature on chest radiograph; but multi-lobar involvement was more common. In our series, B. pseudomallei was most
commonly sensitive to cefoperazone-sulbactam (100%), imipenem(100%) and ceftazidime (98.6%). Only half (51.4%) of our
patients received appropriate empirical antibiotics and the mortality was 71% (63.6% of the death occurring within 48 hours
of admission). Among 18 patients who survived and were discharged well, only 10 (55.6%) received at least one appropriate
antibiotic for at least two weeks, 6 patients (33.3%) received one of the appropriate antibiotics but for less than two weeks
and the remaining patients received other antibiotics. 16.6% had culture proven relapses.
CONCLUSION
Pulmonary melioidosis is commonly associated with diabetes mellitus and has a highly mortality rate.
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ENDOBRONCHIAL ACTINOMYCOSIS: IS A REPEAT BRONCHOSCOPY AFTER
TREATMENT NECESSARY?
S H HOW, KALA*, AZIAN ABD AZIZ
Kulliyyah of Medicine, International Islamic University Malaysia, Kuantan, Pahang, Malaysia
*Department of pathology, Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia
Actinomycosis is a chronic granulomatous infection that becomes suppurative resulting in abscesses and draining sinuses.
Endobronchial actionomycosis is rare and has been reported in association with foreign body aspiration, bronchogenic
carcinoma and endobronchial lipoma. A 51 year old lady presented with a history of chronic cough for 18 months.
Physical examination revealed fine crepitation and rhonchi in the base of the right lung. Contrast enhanced chest computed
tomogram revealed a right middle lobe consolidation with air-bronchogram. Bronchoscopy showed nodular lesions causing
subtotal occlusion of the middle lobe bronchus. Biopsy of these lesions revealed filamentous-like bacterial colonies which
were Gram stain positive and modified Ziehl-Neelson stain negative with a background of acute and chronic inflammation
consistent with actinomycosis. She was treated with penicillin for 7 months. Repeat bronchoscopy showed nodular lesions
in the right main bronchus appeared smaller and a piece of “tissue” at the bifurcation of the middle bronchus which was
removed with forceps. Oral penicillin at the same dose was continued. Three months later, another bronchoscopy showed
complete resolution of the right main bronchus nodule. Therefore, it is essential to repeat bronchoscopy after treatment
of to endobronchial actinomycosis to exclude a concomitant tumour or foreign bodies even if the initial bronchoscopy does
not revealed such abnormalities.
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FOREIGN WORKERS WITH TUBERCULOSIS IN CHEST CLINIC, PENANG HOSPITAL
ABDUL RAZAK M, ABDUL RASHID R,
Respiratory Clinic, Penang Hospital, Penang, Malaysia
BACKGROUND
Malaysia still depends on the foreign workers in several industries and construction sites. The intake of foreign workers
depends on the government policy and agreement with the foreign countries. As for now, Indonesia, Bangladesh, Thailand
and Nepal are countries where these workers are recruited. A medical examination is expected to be done in the country
of origin. One year after working in Malaysia, another medical examination is performed. The strictness of medical
examination in the country of origin is questionable as these workers were noted to have infectious diseases on arrival to
Malaysia. This study shows the number of foreign workers noted to have tuberculosis while in Malaysia. A small number also
have HIV infection.
METHODS
All foreign workers diagnosed with tuberculosis in the Respiratory Clinic were recruited. The registries of the foreign workers
with tuberculosis were retrospectively reviewed for the year 2004.
RESULTS
A total of 32 patients were detected to have TB in 2004. There were 17 male (53%) and female 15 (47%). The largest number
of patients were from Indonesia (44%) followed by Indian and Myanmar each 16%. Most of the patients were young adults
about 20 to 30 years of age (72%). Pulmonary tuberculosis constitute 60% while extra-pulmonary tuberculosis is 40%.
The commonest extrapulmonary presentation was lymph node swelling at the neck (85%). All the patients with pulmonary
tuberculosis presented with cough (100%), 79% presented with other associated symptoms like fever, loss of appetite,
loss of weight and cough. Only 16% presented with haemoptysis. The symptoms of cough were present for more then one
month in 68% of the cases with pulmonary TB. 17/19 patients with pulmonary TB had severe chest x-ray changes.
Eight patients (25%) were referred by general practitioners while 47% was referred by government clinic, the rest were
referred by government specialist clinics (surgical and ENT clinics). Only 28% of the foreign workers have history of contact
with a TB patient.
Majority of the workers were working in factories (43%), building construction laborers (18%) and house maid (12%).
Six  patients (19%) were also co-infected with HIV virus.
CONCLUSION
Infectious pulmonary TB is still noted in the foreign workers who are working in areas where there is close proximity with
other local and foreign workers. This can contribute to be a source of infection and an increase in the number of TB in the
country. Medical examination should be done on entry and yearly examinations to exclude late manifestations of infectious
diseases.
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DIAGNOSTIC YIELD OF PERIPHERAL LYMPH NODE BY FINE NEEDLE ASPIRATION
ABDUL RAZAK MUTALIF, ABDUL RASHID RAZAK*
Department of Respiratory Medicine, Penang Hospital, Penang, Malaysia
*AIMST College, Sungai Petani, Kedah, Malaysia
BACKGROUND
Tuberculosis (TB) is a common problem in developing countries. More then 80% of cases are pulmonary TB while about 20%
are due to extra-pulmonary TB. Lymph node tuberculosis is the commonest presentation in patients with extra-pulmonary TB.
Diagnosis of lymph node TB can be arrived by performing needle biopsy in an out-patient clinic.
METHODS
All patients with TB lymph node diagnosed in year 2004 in Respiratory Clinic, Hospital Pulau Pinang were reviewed.
The data from the TB Registration card and biopsy reports were  collected retrospectively. The needle aspiration was done
by using a 18 gauge needle and plunger with 10 ml syringe.
RESULTS
Slight female preponderance 32/58 (55%), more then 60% of the patients were in the age group between 20 and 40 years.
Abnormal chest x-ray was noted in 66% and only 8 (14%) had sputum for acid fast bacilli (AFB) positive. There were 19 (33%)
with caseous necrosis, 26 (45%) with granulomatous inflammation and and 17 (30%) has lymph node aspiration with AFB
positive smear. In this study, it was also noted that 9 patients (16%) had human immunodeficiency virus (HIV) co-infection.
CONCLUSION
This study shows that out-patient fine needle aspiration is a simple and fast way of diagnosing lymph node TB. In the era
of HIV and TB co-infection, extrapulmonary TB especially lymph node TB is a common presentation. This procedure is safe,
well tolerated and has good diagnostic yield.
PP  19
IS THE HEAVY WORKLOAD OF THE LABORATORY TECHNICIANS A CAUSE FOR POOR YIELD
OF SPUTUM ACID FAST BACILLI SMEAR MICROSCOPY? 
ADEL HAMOOD NOMAN, ABDUL RAZAK M*
School of Pharmacy, Universiti Sains Malaysia, Penang, Malaysia
*Respiratory Clinic, Penang Hospital, Penang, Malaysia
BACKGROUND
The main method of diagnosing pulmonary tuberculosis (TB) is by sputum microscopy for Acid Fast Bacilli (AFB). In most
government hospitals and clinics, the symptomatic examination for sputum AFB microscopy is very low. As the symptomatic
examination is low, the yield is also low. This can be due to many factors like: sputum not sent for microscopy, poor sputum
specimen, sputum quantity is low for microscopy, patients did not give specimen for examination, sputum AFB microscopy
not requested by doctor and technical problems with the microscopes and staining methods. The workload of the laboratory
technician may also be a reason for the poor yield. This study is to look into the workload of these technicians involved
in sputum AFB microscopy.
METHODS
This is a retrospective study conducted on four hospitals and four clinics in the state of Penang. All sputum microscopy
for AFB done in the year 2003, in these clinics were reviewed. According to guidelines by WHO/IUATLD, on the workload
of laboratory technicians for AFB: heavy workload if > 20 smears/day/technician and low workload if < 15
smears/week/technician.
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RESULTS
Sputum AFB smear positive for Hospitals A, B, C and D were 144, 47, 106 and 2 cases respectively and for Clinics E, F, G
and H are 23, 0, 0 and 6 cases respectively. Attendance of patients for the hospitals and clinics were 1863, 390, 2134, 563,
1212, 347, 272 and 816 patients respectively. Based on Spearmen correlation test, the number of patients has direct
correlation to the sputum AFB positive results (p = 0.011). The following were the workload of sputum AFB microscopy of the
hospitals and clinics per day respectively: 20.7, 4.3, 23.7, 6.2, 13.2, 3.9, 3.0 and 8.8. Only two hospitals, Hospital A and C,
had values more then 20 smears/day/technician. When workload was calculated per week per technician, all were more then
15 (143, 30, 164, 43, 93, 26, 20 and 61).
CONCLUSION
This study shows that the technicians were not overworked or under working, though two hospitals showed values more
then 20. The results were between heavy and low workload (< 20 smears/day/technician and > 15 smears/week/technician).
The low sputum AFB yield is not due to technician’s load of working, other factors play a role which need to be identified
for better symptomatic investigations and yield.
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CUTANEOUS ADVERSE DRUG REACTION (CADR) FROM 1ST LINE ANTITUBERCULOSIS DRUGS
AMONG PATIENTS TREATED FOR ACTIVE TUBERCULOSIS – RESPIRATORY UNIT,
PENANG HOSPITAL 2004 
ONG C K, TAN W C*, ABDUL RAZAK M
Respiratory Unit, Penang Hospital, Penang, Malaysia
*Department of Dermatology, Penang Hospital, Penang, Malaysia
INTRODUCTION
First line Anti-TB therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol/streptomycin is very effective.
However, major adverse reactions to antituberculous drugs can cause significant morbidity and mortality, and compromise
treatment regimens for tuberculosis (TB). CADR is one of the commonly observed major side effects.
OBJECTIVES
To determine pattern of CADR that is commonly associated with anti-TB therapy.
To determine drug(s) that commonly cause CADR in patients treated for TB.
To determine the role of various risk factors in the development of CADR in patients receiving anti-TB therapy.
METHODOLOGY
This retrospective study looked at the cases of adult active TB treated in Respiratory Unit, Penang Hospital from
January 2004 to December 2004. The information were obtained from patient’s medical report, TB booklet and in-patient
record (if they were admitted before).
RESULTS
Of a total of 381 patients treated for active TB, 23 patients (12 females; 11 males) developed CADR (6.0%). 11 of 23 patients
were Chinese, Malay 7 patients, Indian 4 patients and 1 foreigner. The common patterns of CADR observed include
morbiliform rash (74.0%), Stevens-Johnson Syndrome (8.7%), erythema multiforme (4.3%) and others (which include
exfoliative dermatitis and lichenoid eruption). 60.8% of events occurred between 1 week to 1 month in relation to initial dose.
In all the patients, skin rash improved following dechallenge. All patients presented with itchy skin rash. Other presentations
include fever, facial swelling, oral ulcer, etc. Among the first line anti-TB drugs, pyrazinamide was the commonest offending
drug (47.8%), followed by rifampicin (26.1%), isoniazid (21.7%), ethambutol (17.4%) and streptomycin (13.0%). Various risk
factors were identified, which include polypharmacy (30.4%), HIV infection (21.7%), autoimmune disorders (8.7%),
chronic renal failure (8.7%), liver disease (4.3%). None of our patients have previous history of drug allergy or malignancy.
CONCLUSION
The incidence of CADR was highest with Pyrazinamide, associated with HIV infection and polypharmacy. Risk of CADR
observed among males and females were comparable in our study. CADR is a diagnosis of high index of suspicion especially
in those having itchy skin rashes between 1 week to 1 month in relation to initial dose of anti-TB.
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A CASE 0F α1 – ANTITRYPSIN DEFICIENCY IN AN 81-YEAR OLD LIFE TIME NON SMOKER – 
ARE OTHER FACTORS INVOLVED?
JAMALUL AZIZI ABDUL RAHMAN*/**, JOHN WOODS*, NEIL MISSO*
*Asthma and Allergy Research Institute, University of Western Australia, Nedlands, Western Australia, Australia
**Division of Respiratory Medicine, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia
α1-antitrypsin deficiency is a rare cause of emphysaema. Patients often present in the third or fourth decade of life leading
to early death. We report the details of an 81-year-old man who has emphysaema secondary to α1-antitrypsin deficiency.
He first presented with symptoms of dyspnoea at age 74, had a radiographic diagnosis of emphysaema at age 76 and is still
alive at age 81.
He had worked as an engineer in a timber mill and had no known exposure to environmental toxins. His mother was a
non-smoker who also suffered from emphysaema. He is a life-long non-smoker. His α1-antitrypsin level on two occasions was
0.4 g/L and 0.3 g/L (phenotype ZZ, normal 0.8 to 2.0 g/L).
He was evaluated for lung volume reduction surgery but he was deemed unsuitable due to his lower lobe predominant
disease and therefore referred for pulmonary rehabilitation programme.
He is one of the oldest patients to be diagnosed with this condition in the world and this raises questions as to whether other
factors may be important in the presentation of α1-antitrypsin deficiency.
Key words: α1-antitrypsin, emphysaema, case report
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CYSTEINYL LEUKOTRIENES AND PROSTAGLANDIN E2 IN INDUCED SPUTUM OF
PATIENTS WITH EOSINOPHILIC OR NON-EOSINOPHILIC ASTHMA
SHASHI AGGARWAL, NEIL MISSO, PHILIP THOMPSON
Asthma & Allergy Research Institute and CRC for Asthma, The University of Western Australia,
Nedlands, Australia
Airway inflammation in asthmatic patients results in the production of cysteinyl leukotrienes (cysLT), by eosinophils and
mast cells as well as prostaglandin E2 (PGE2) by airway epithelium and macrophages.
AIM
To determine whether the concentrations of cysLT and PGE2 in induced sputum are associated with eosinophilic or
non-eosinophilic airway inflammation in asthma.
METHODS
Hypertonic saline was used to induce sputum in 38 asthmatic patients, 10 of whom were categorised as having sputum
eosinophilia (≥ 2% sputum eosinophils). Specific enzyme immunoassays were used to measure the concentrations of
cysLT and PGE2 in sputum supernatants of patients with (n = 10) and without (n = 28) sputum eosinophilia.
RESULTS
For all asthmatic patients the percentage of eosinophils in sputum was negatively correlated with FEV1 (Rho = – 0.5,
P = 0.002). CysLT concentrations were correlated with the percentage of sputum eosinophils (Rho = 0.64, P < 0.05)
in patients with sputum eosinophilia. CysLT concentrations were significantly higher (P < 0.05), while PGE2 concentrations
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were significantly lower (P < 0.025) in asthmatic patients with sputum eosinophilia. For all asthmatic patients, urinary LTE4
concentration was correlated with the percentage of sputum eosinophils (Rho = 0.41, P = 0.01) and patients with sputum
eosinophilia had significantly higher urinary LTE4 concentrations compared with patients without sputum eosinophilia
(P = 0.003).
CONCLUSION
Increased airway cysLT and urinary LTE4 concentrations and decreased PGE2 concentrations in the airways may contribute
to airway inflammation in patients with eosinophilic asthma.
Supported by the CRC for Asthma
Key words: asthma, inflammation, eosinophils, leukotrienes
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PERCEPTION TOWARDS ASTHMA CLINICAL PRACTICE GUIDELINES –
A COMPARISON BETWEEN GOVERNMENT AND PRIVATE DOCTORS IN MALAYSIA
LI-CHER LOH, PEI-SE WONG
IMU Lung Research, International Medical University, Kuala Lumpur, Malaysia
A self-answered, anonymously completed, nationwide questionnaire survey was conducted between June 2002 and
May 2003 among Malaysian doctors through post and medical meetings. Findings based on 116 government and 110 private
doctors satisfactorily completed forms (effective respondent rate: 30.1%) showed that more than 70% of government and
private doctors claimed familiarity with asthma CPGs but proportionately more private doctors considered them
“unworkable” and were reluctant to adopt them in their practice setting, quoting cost as the primary reason.
Albeit the shortcomings of such survey, our findings suggest that medical resource cost is an important concern in the
acceptance of asthma CPGs recommendations and should be addressed more thoroughly.
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EFFECT ON ASTHMA SEVERITY CLASSIFICATION AND TREATMENT APPROPRIATENESS WHEN
SPIROMETRY IS USED FOR ASSESSMENT
LI-CHER LOH
IMU Lung Research, International Medical University, Clinical School, Seremban, Negeri Sembilan, Malaysia
Current asthma treatment is directed by severity of symptoms and lung function. In Malaysia, spirometry is not widely
available and therefore not used in most medical consultations. In 163 asthmatic patients [mean (95% CI)
age: 41 (38 – 44) yrs; 29% male; 32% Malays, 32% Chinese, 34% Indians] who were being followed up in a State Hospital
medical outpatient clinic and a large urban-based health clinic, we studied the effect on Global Initiative for Asthma (GINA)
disease severity classification and the appropriateness of currently prescribed treatment when Forced Expiratory Volume
in One Second (FEV1) was considered together with symptoms severity. We showed that as a result, 52% of the patients were
upgraded to a higher severity classification, compared to 11% who were downgraded to a lower severity, and 71% of the
patients were “under-treated” compared to 5% who were “over-treated”. If based on “symptoms alone” to assess severity,
39% of the patients were still “under-treated”, compared to 19% of the patients who were “over-treated”. We concluded that
the disease severity in many asthmatic patients might have been underestimated and therefore not adequately treated,
because spirometry was not available or used to assess asthma severity. The use of spirometry, or at least peak flow meter,
should be advocated more widely among clinicians treating asthma in Malaysia.
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ASTHMA AND OBESITY IN THE PAEDIATRIC CLINIC
ARFAH ABU BAKAR, KEW YUEN CHENG, MOHD FARUQI UZAIR MOHAMED SIDEK,
NORBAIZATUL AKHMAL ZULKEFLY, SITI HALIMAHTUN SAHAB, JESSIE A DE BRUYNE, MOHD YAZID JALALUDIN
Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
INTRODUCTION
Asthma is a common condition occurring in 7 – 16% of the paediatric population in the Klang Valley and has been increasing
in prevalence (ISAAC). Obesity is a complex multi-factorial chronic disease that develops from an interaction of genotype and
environment. There has been a rising trend in obesity worldwide. It is believed that there is an association between asthma
and obesity. The rise in childhood asthma could be linked to the surge in obesity. This study was conducted to look
at a possible link between asthma and obesity in children attending clinic in University Malaya Medical Centre (UMMC).
METHODOLOGY AND MATERIALS
Subjects included successive patients attending the paediatric asthma clinic (n = 67), the general paediatric clinic (n = 67)
and the paediatric obesity clinic (n = 36) within a one-month period in 2005. The notes of patients attending the paediatric
asthma and respiratory clinics were reviewed and Body Mass Index (BMI) was calculated from their recorded heights and
weights. This group was compared with children attending the general paediatric clinic. Obese children attending the
paediatric obesity clinic were interviewed using the International Study of Asthma and Allergy in Childhood (ISAAC)
questionnaire too look for the prevalence of asthma symptoms in this group.
RESULTS AND DISCUSSION
Obesity was significantly more common amongst asthmatic patients (20.9%) than amongst patients attending the general
paediatric clinic with other problems (11.9%) (p < 0.05). Asthma was very prevalent in the patients attending the obesity clinic
all of whom had a body mass index (BMI) above 30 – 27.8% had previous symptoms of asthma and 19.4% had current asthma
i.e. half had ever had symptoms of asthma which is far higher than in the general population.
There is a positive link between asthma and obesity in our clinic patients Obesity is a pro-inflammatory condition and may
facilitate the development of asthma through immune mechanisms. Public misperception about ability to exercise and also
consumption of high calorie food may increase the risk of obesity among asthmatic patients. Asthma control may be
improved by educating the children to consume a balanced and nutritious diet and by increasing physical activities in order
to reduce weight.
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THE PREVALENCE OF TUBERCULOSIS (TB) AMONG HUMANIMMUNODEFICIENCY VIRUS (HIV)
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INTRODUCTION
People living with HIV/AIDS are at increased risk of contracting TB1. HIV infection is the strongest known risk factor
for reactivation of a latent TB infection1.
METHODOLOGY
Mantoux test was done on 100 HIV positive inmates at a drug rehabilitation center. Those who had a positive mantoux test
and symptomatic inmates had chest radiographs done.
RESULTS
Three of the 100 inmates were found to have tuberculosis ie. a 3% positive pick up rate.
CONCLUSION
Active case finding in HIV infected persons is an effective way of detecting TB disease.
Keywords: TB, HIV
M A L A Y S I A N  T H O R A C I C  S O C I E T Y  –  8 t h A N N U A L  C O N G R E S S
59
